This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use:

This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated.
A copy can be downloaded for personal non-commercial research or study, without prior permission or charge.
This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author.
The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author.
When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given.
A cognitive behavioural approach to functional neurological disorder: a systematic review, meta-analysis and grounded theory study

Emily R. Revell, PhD

Doctorate in Clinical Psychology
The University of Edinburgh

May 2019
DClinPsychol Declaration of Own Work

Name: Emily Revell

Title of Work: A cognitive behavioural approach to functional neurological disorder: a systematic review, meta-analysis and grounded theory study

I confirm that this work is my own except where indicated, and that I have:

- Read and understood the Plagiarism Rules and Regulations
- Composed and undertaken the work myself
- Clearly referenced/listed all sources as appropriate
- Referenced and put in inverted commas any quoted text of more than three words (from books, web, etc.)
- Given the sources of all pictures, data etc. that are not my own
- Not made undue use of essay(s) of any other student(s), either past or present (or where used, this has been referenced appropriately)
- Not sought or used the help of any external professional agencies for the work (or where used, this has been referenced appropriately)
- Not submitted the work for any other degree or professional qualification except as specified
- Acknowledged in appropriate places any help that I have received from others (e.g. fellow students, technicians, statisticians, external sources)
- Complied with other plagiarism criteria specified in the Programme Handbook
- I understand that any false claim for this work will be penalised in accordance with the University regulations
- Received ethical approval from the School of Health in Social Science, University of Edinburgh
  OR
- Received ethical approval from an approved external body and registered this application and confirmation of approval with the School of Health in Social Science’s Ethical Committee

Signature

Date...21/10/2019...
Contents

Table of Tables ................................................................................................................. 4
Table of Figures .................................................................................................................. 4
Abstract ............................................................................................................................... 5
Lay summary ......................................................................................................................... 6
Acknowledgements ........................................................................................................... 7

1 Cognitive behavioural therapy for functional neurological symptoms: a systematic review and meta-analysis ......................................................................................... 8
  1.1 Abstract ...................................................................................................................... 9
  1.2 Introduction ................................................................................................................ 10
    1.2.1 Symptoms and comorbidity .............................................................................. 10
    1.2.2 Mechanism ......................................................................................................... 11
    1.2.3 Intervention ....................................................................................................... 12
  1.3 Methods ................................................................................................................... 13
    1.3.1 Data sources ..................................................................................................... 13
    1.3.2 Study inclusion .................................................................................................. 14
    1.3.3 Data extraction ................................................................................................ 15
    1.3.4 Meta-analysis .................................................................................................... 16
  1.4 Results ...................................................................................................................... 17
    1.4.1 Corpus of studies .............................................................................................. 17
    1.4.2 Target of intervention ....................................................................................... 17
    1.4.3 Type of intervention ......................................................................................... 17
    1.4.4 Quality assessment .......................................................................................... 27
    1.4.5 Outcomes .......................................................................................................... 29
  1.5 Discussion ................................................................................................................ 34
    1.5.1 Limitations ....................................................................................................... 35
    1.5.2 Clinical implications ......................................................................................... 35
    1.5.3 Conclusions ...................................................................................................... 36

2 Developing a cognitive behavioural understanding of idiopathic drop attacks in the context of functional neurological disorder: a grounded theory study ........................................................................ 42
  2.1 Abstract ................................................................................................................... 43
  2.2 Introduction .............................................................................................................. 44
    2.2.1 Prevalence ........................................................................................................ 44
    2.2.2 Frequency ......................................................................................................... 44
    2.2.3 Associations .................................................................................................... 45
    2.2.4 Impact ............................................................................................................... 45
    2.2.5 Mechanism ....................................................................................................... 45
    2.2.6 Therapeutic intervention ................................................................................. 46
    2.2.7 Aims ............................................................................................................... 47
2.3 Methods ......................................................................................................................... 47
  2.3.1 Participants ................................................................................................................. 47
  2.3.2 Design ......................................................................................................................... 48
  2.3.3 Procedure ..................................................................................................................... 48
  2.3.4 Data collection .......................................................................................................... 49
  2.3.5 Analysis ....................................................................................................................... 49
2.4 Results ............................................................................................................................. 50
  2.4.1 Main themes .............................................................................................................. 51
  2.4.2 Emergent theory ....................................................................................................... 58
2.5 Discussion ......................................................................................................................... 60
  2.5.1 Integration of findings to existing literature ............................................................. 60
  2.5.2 Methodological limitations ...................................................................................... 62
  2.5.3 Clinical implications and future research ................................................................. 62
  2.5.4 Conclusion .................................................................................................................. 63
References .............................................................................................................................. 67

Appendices
  Appendix A: Author guidelines for Neuropsychology Review
  Appendix B: PRISMA checklist
  Appendix C: Author guidelines for Epilepsy & Behavior
  Appendix D: Ethical approval letters
  Appendix E: Study protocol
  Appendix F: Interview schedule
  Appendix G: Diary prompt sheet
  Appendix H: Excerpt of transcript and initial codes
  Appendix I: Funnel plots

Total word count (excluding references): 16,573
Table of Tables

Table 1.1 Summary characteristics of included studies ................................................................. 19
Table 1.2 Quality assessment ratings, using the EPHPP quality assessment tool (Thomas et al., 2004) ........................................................................................................................................................................ 28
Table 2.1: Themes and supporting quotes within the predisposing factors category .......... 52
Table 2.2: Themes and supporting quotes within the precipitating factors category .......... 53
Table 2.3: Themes and supporting quotes within the maintaining factors category .......... 56

Table of Figures

Figure 1.1 Flow diagram of study identification and inclusion ...................................................... 15
Figure 1.2 Forest plot of the post-intervention effect of CBT on daily functioning, compared to control .......................................................................................................................................................... 30
Figure 1.3 Forest plot of the pre-post effect sizes of CBT on daily functioning .................... 30
Figure 1.4 Forest plot of the post-intervention effect of CBT on functional neurological symptoms, compared to control ........................................................................................................ 31
Figure 1.5 Forest plot of the pre-post effect sizes of CBT on functional neurological symptoms ......................................................................................................................................................... 31
Figure 1.6 Forest plot of the post-intervention effect of CBT on anxiety symptoms, compared to control .................................................................................................................................................................. 32
Figure 1.7 Forest plot of the post-intervention effect of CBT on depression symptoms, compared to control .................................................................................................................................................... 32
Figure 1.8 Forest plot of the pre-post effect sizes of CBT on anxiety symptoms .................. 33
Figure 1.9 Forest plot of the pre-post effect sizes of CBT on depression symptoms .......... 33
Figure 2.1: Participant flowchart ........................................................................................................ 48
Figure 2.2: Main categories and themes ......................................................................................... 51
Figure 2.3: Grounded theory model of idiopathic drop attacks .................................................... 59
Abstract

**Introduction:** Functional neurological symptoms are commonly reported by people presenting to neurology services. Symptoms are diverse, and there is little published evidence to inform treatment guidelines. Idiopathic drop attacks are also seen within neurology services, but literature about them is sparse and it is unclear whether they should be considered within the spectrum of functional neurological disorder.

**Aims:** The aim of this thesis was to assess cognitive behavioural therapy (CBT) as an intervention for functional neurological disorder (FND), through a systematic review and meta-analysis. A second aim was to look at idiopathic drop attacks and determine whether a psychological understanding of these would help to inform formulation and treatment.

**Methods:** A systematic review identified 28 studies of CBT for FND, nine of which were included in meta-analysis. In addition, a grounded theory study of idiopathic drop attacks was conducted through the coding and synthesis of data from interviews and diaries of seven individuals with FND, with the aim of identifying predisposing, precipitating and maintaining factors.

**Results:** In the systematic review and meta-analysis, random effects models revealed a significant advantage of CBT over control on daily functioning, and a significant improvement within CBT groups over time. CBT also had a significantly positive effect on anxiety, depression and functional neurological symptoms, both compared to control groups, and within CBT groups over time. Positive effects of CBT were maintained over six months.

In the grounded theory study, themes relating to predisposing and precipitating factors for drop attacks, along with thoughts, emotions and behaviour both before and after a fall, were identified. A cognitive behavioural model was proposed, with a traumatic first fall and life stressors as predisposing factors, situational triggers and increased worry as precipitating factors, and a maintaining cycle of thoughts, emotion and behaviour.

**Conclusions:** Meta-analysis suggests that CBT may be effective for FND, and that the positive impact of this persists over time. However, as the evidence base is currently small, larger trials are required. The grounded theory study proposed a cognitive behavioural understanding of the onset and maintenance of idiopathic drop attacks and noted considerable overlap between drop attacks and non-epileptic seizures. This understanding could help to guide formulation, and suggests a CBT treatment approach would be worth exploring in this population.
Lay summary

Functional neurological disorder is a term used to describe symptoms which are similar to those seen in neurological illnesses, but which are not due to disease. They are common in people who go to neurology clinics. Symptoms vary, and there is little published evidence to inform the best course of treatment. Idiopathic drop attacks are unexplained falls to the floor, and are also seen within neurology services, but it is unclear whether they should be considered a functional neurological disorder.

This thesis contains two papers. The aim of the first was to assess whether cognitive behavioural therapy (CBT; a psychological intervention which focuses on thoughts and behaviour) was an effective treatment for functional neurological disorder (FND), through reviewing the evidence. The second paper aimed to look at idiopathic drop attacks and determine whether a psychological understanding of these would help to inform treatment.

In our review, we found 28 studies of CBT for FND. Results from nine high-quality studies were synthesised and we found that CBT improved everyday functioning, anxiety, low mood and functional neurological symptoms.

For the second paper, we interviewed seven people who were experiencing drop attacks, and asked them to keep diaries of their falls. We found that participants had experienced a traumatic first fall and noted that stressful life experiences may have made the falls more likely to happen. People were more likely to fall in certain places, and when they were feeling more stressed or worried. We also found that people were more likely to cope with their falls by avoiding certain situations.

Overall, the first study concluded that CBT seems to be an effective treatment for FND, but we need more high-quality research to determine this. The second study found that drop attacks are very similar to other functional neurological symptoms and that a CBT treatment approach could be helpful.
Acknowledgements

Firstly, a very big thank you to the participants who took part in the drop attack study – this thesis would have been impossible without you.

Thank you to my supervisors Dr Paul Morris and Dr David Gillespie for their advice and encouragement throughout the project. A special thanks to Prof Jon Stone whose advice and expertise were invaluable in designing and carrying out this project. I am also very grateful to Laura Corfield for her role in co-rating papers for the systematic review.

Lastly, a special thank you to Ruairi for supporting me, emotionally and practically, through the last three years (and the seven before that to get to this point!), and to Finn for giving me the best sense of perspective.
1 Cognitive behavioural therapy for functional neurological symptoms: a systematic review and meta-analysis

Emily R. Revell a,b, David Gillespie a, Jon Stone a, Paul G. Morris b

a Department of Clinical Neurosciences, NHS Lothian, Western General Hospital, Edinburgh, EH4 2XU, UK
b Clinical and Health Psychology, School of Health in Social Science, University of Edinburgh, Edinburgh, EH8 9AG, UK

*Corresponding author: Emily R. Revell

Manuscript prepared for submission to Neuropsychology Review (https://www.springer.com/biomed/neuroscience/journal/11065/PSE). Author guidelines are included in Appendix A.

Funding: No external funding was sought or provided for this review.
1.1 Abstract

Functional neurological symptoms are common in those who present to neurology services. However, currently there is a sparse evidence base to inform treatment. Cognitive behavioural therapy (CBT) is an intervention which has been trialled with different functional neurological disorder (FND) presentations. We systematically reviewed CBT trials for FND to investigate its efficacy on daily functioning, functional neurological symptoms, and anxiety and depression symptoms.

Electronic databases were systematically searched for studies investigating CBT for FND, and 28 studies with a total of 1010 participants were identified. Nine of these, including seven controlled trials, were of a methodological quality that allowed them to be combined in meta-analysis.

Random effects models revealed a significant advantage of CBT over control on daily functioning (g=-0.44, 95% CI -0.66, -0.22, p<0.0001), and a similar effect size was seen within CBT groups over time (d=-0.50, CI -0.76, -0.24, p=0.0002). CBT also had a significantly positive effect on anxiety, depression and functional neurological symptoms, both compared to control and over time. At six- to twelve-month follow-up, positive effects of CBT had been maintained.

CBT improved daily functioning, anxiety, depression and functional neurological symptoms for those with FND, and these persisted once treatment had ended. However, the generalisability of the estimates of effect produced here are limited due to the small number of small heterogeneous trials. CBT is a promising intervention for FND, and further large-scale trials would help to determine its efficacy.

Keywords: Cognitive behavioural therapy; functional neurological disorder; functional neurological symptoms
1.2 Introduction

Functional neurological disorder (FND) is a term which describes neurological symptoms which do not have an identified organic cause. DSM-5 (APA 2013) criteria for FND state that there must be A) One or more symptoms of altered voluntary motor or sensory function, B) Clinical findings that provide evidence of incompatibility between the symptom and recognised neurological or medical conditions, C) Symptoms or deficits that are not better explained by another medical or mental disorder, and D) Symptoms or deficits that cause clinically significant distress or impairment in social, occupational, or other important areas of functioning, or warrants medical evaluation.

The prevalence of FND has been estimated at 9-30% of those presenting to neurology inpatient and outpatient settings (Stone et al. 2009; Lempert et al. 1990) with follow-up at 18 months showing this initial diagnosis to be accurate in all but 0.4% of cases (Stone et al. 2009). A large study in Scotland estimated that neurologists were diagnosing around 5000 cases of FND per year (Stone et al. 2010a).

Functional symptoms often persist over time, leading to increased costs to the health service and to the wider economy, due to reduced capacity for work (M Reuber et al. 2005). Direct healthcare costs alone in Scotland have been estimated to be £11.3 million, with 27% of patients also receiving benefits, and 50% unable to work (Stone et al. 2010a; Carson et al. 2011). Therefore it is important that research highlights effective and acceptable treatments.

1.2.1 Symptoms and comorbidity

A wide variety of symptoms are included under the FND classification. These include paralysis, weakness, seizures, visual problems and speech problems. Other functional symptoms are often co-morbid with FND, such as chronic pain, headache and chronic fatigue (Carson et al. 2000). Although these have separate evidence bases, there are increasing calls for a transdiagnostic approach to functional symptoms, given the similarities and comorbidity between them (Chalder and Willis 2017). However, for the purposes of this review, the focus will be on functional neurological symptoms, as included in previous reviews of this population (Ludwig et al. 2018; Hopp and LaFrance 2012).

The pattern of functional neurological symptoms can vary widely between individuals, with some having a single symptom and some multiple. The frequency and persistence of these symptoms also varies, and people may experience a single acute episode, intermittent symptoms or a more chronic course. This has raised questions about whether FND should have a single classification or whether certain presentations, such as specific clusters of symptoms, should be categorised separately (Stone et al. 2011; Carson and Lehn 2016).

One of the most researched functional neurological presentations is non-epileptic seizures (NES), also termed ‘psychogenic seizures’, ‘dissociative seizures’, ‘functional seizures’ and
‘non-epileptic attack disorder’. These are ‘episodes of altered movement, sensation, or experience resembling epileptic seizures, but not associated with ictal electrical discharges in the brain’ (M Reuber 2009). Functional motor disorders (FMD), which is a term that covers several presentations such as weakness, gait disorders and tremor, have also been widely studied (Ricciardi and Edwards 2014). Less research has been conducted with other presentations, such as functional dizziness (Popkirov et al. 2018).

Comorbidity between functional neurological symptoms is common. A six-year follow-up of 73 patients with functional motor symptoms found that 44% had experienced other unexplained neurological symptoms (Crimlisk et al. 1998). A more recent study of functional weakness compared 107 patients with functional weakness to 46 patients with a neurological weakness. Those with functional weakness were significantly more likely to also experience other functional symptoms, such as non-epileptic seizures, functional tremor and functional dystonia (Stone et al. 2010b).

Stone et al. (2010b) also found those with functional weakness to be significantly more likely to meet diagnostic criteria for other psychiatric disorders, including major depression, panic, generalised anxiety disorder and somatisation disorder. Seventy-five percent of the sample in Crimlisk and colleagues’ (1998) study also met the criteria for other psychiatric disorders.

1.2.2 Mechanism

There are a number of theoretical understandings of functional neurological disorders. Originally, functional symptoms were conceptualised as ‘hysterical conversion’ by Breuer and Freud (2009). The functional symptom was seen as a physical representation of repressed thoughts and emotions. More recently, the main model of functional symptoms has been the somatosensory amplification model (Barsky and Wyshak 2018), which states that stress related physical arousal and attention on physical symptoms leads to the misattribution of normal physical sensations to disease. Over time, with increased attention on physical symptoms, tolerance decreases and arousal increases, further exacerbating physical arousal symptoms (Nakao and Barsky 2007). Until recently, this has been the central basis of cognitive behavioural models of functional symptoms. However, it has not fully explained how subjective and measured stress levels can be lower in those with functional symptoms (Tak et al. 2011).

The predominant current understanding of functional symptoms is a Bayesian predictive coding framework. A comprehensive model of functional symptoms was outlined by Van den Bergh and colleagues (2017), based on a review of the functional symptom literature. The authors suggest that functional symptoms are a set of perceptions, based on the brain’s interpretation of information from the body, which is guided by past experience. A cognitive representation of a symptom, which is preconscious in nature, is activated when certain triggers are present, such as physiological stress, or contextual triggers. This helps to
explain symptoms which occur in the absence of subjective stress, and highlights the importance of the individual’s interpretation of symptoms, and the context in which they occur.

1.2.3 Intervention

At present there are no official treatment guidelines, due to limited randomised controlled trial evidence, however various approaches have been trialled, including antidepressant use (Voon and Lang 2005), hypnotherapy (Moene et al. 2002), and physical therapy (Nielsen et al. 2013). Psychological therapies have also been investigated, including CBT, psychodynamic therapy, paradoxical intention therapy, mindfulness, psychoeducation, and eclectic interventions. A meta-analysis of these interventions for NES found them to reduce seizure frequency by at least 50% in 82% of participants, and psychological intervention led to seizure freedom in 47% of the participants in the review (Carlson and Perry 2017).

A stepped care approach to FND was developed by a group of healthcare professionals, as part of an NHS Scotland healthcare improvement project (2012). The treatment approach outlined in the NHS Scotland report recommended that, following diagnosis, a brief, guided cognitive behavioural self-help programme should be delivered if required, following positive results from a randomised controlled trial (RCT) of such an intervention (Sharpe et al. 2011). However, this type of intervention may not be suitable for all patients with FND, as a degree of self-motivation is required for guided self-help to be an effective intervention (Coull and Morris 2011).

CBT interventions have been trialled with the most common FND presentations, including non-epileptic seizures (LaFrance et al. 2014), functional motor disorder (Dallocchio et al. 2016) and functional dizziness (Schmid et al. 2018). The approaches tend to have the same basic elements, which involve trying to interrupt current patterns of thoughts and behaviour through identifying negative thoughts and illness beliefs, and engaging in avoided activities in order to reduce any anxiety associated with them. Coping strategies such as relaxation exercises and distraction techniques are also developed as part of these interventions.

CBT has been trialled with non-neurological functional symptoms, with positive results. A recent systematic review and meta-analysis identified 15 RCTs of CBT for ‘somatic’ or ‘medically unexplained’ symptoms. They found CBT to significantly reduce somatic symptoms, anxiety symptoms and depression symptoms, and to improve physical functioning (Jing et al. 2019). However, this review did not include trials of common functional symptom presentations, such as irritable bowel syndrome (IBS) and chronic fatigue syndrome (CFS), and significant heterogeneity within meta-analyses was not taken into account. An earlier meta-analysis of 20 CBT RCTs found the intervention to be effective in reducing physical symptoms of IBS (d=0.73; Laird et al. 2016). An additional meta-
Analysis of 13 studies of CBT for CFS also found CBT to be effective in reducing fatigue compared to controls (d=0.48; Malouff et al. 2008).

Although a previous narrative review of CBT for FND has been completed (Hopp & LaFrance, 2012), this is the first systematic review in this area, as far as we are aware. As CBT is starting to be recommended within treatment guidelines, it is important to assess the expanding evidence base to determine the impact of CBT on different functional neurological symptoms. Given ongoing debates on whether different clusters of symptoms should be treated as separate disorders, or different manifestations of the same underlying process (Carson and Lehn 2016; Stone et al. 2011), this review aimed to give an overall picture of the evidence base of CBT for all functional neurological symptoms.

Our aim was to review the literature on CBT as a treatment for functional neurological symptoms, investigating everyday social and occupational functioning as a primary outcome, along with secondary outcomes of functional neurological symptoms, and symptoms of anxiety and depression.

### 1.3 Methods

The systematic review was conducted following PRISMA guidelines and a checklist is included in Appendix B. The protocol was registered on PROSPERO with reference number CRD42018093988 (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=93988).

#### 1.3.1 Data sources

The Cochrane Register, PsycINFO, EMBASE, MEDLINE and Web of Science were searched, up to November 2018, using the following phrases:

("functional sympto**" OR unexplained OR somati* OR conversion OR hysteri* OR psychogenic OR "dissociative seizure**" OR "non-epilepti**" OR nonepilepti* OR pseudoseizure* OR "functional motor" OR "functional weakness**" OR "functional dystonia" OR "postur*-perceptual" OR PPPD OR "chronic subjective dizziness" or "phobic postural vertigo" or "somatoform vertigo" OR (functional and (dysphagi* or dysphoni* or dysarthri*)) AND ("cognitive therap**" OR "cognitive behav**" OR "beha*v therap**" OR "beha*v treatment**" OR "cognitive treatment**" OR CBT OR "acceptan*c and commitment" OR "dialectical behav**" OR DBT OR CBASP OR "function* analyt**" OR FAP OR "relation* frame" OR mindfu* OR "mind-fu**" OR compassio* OR CFT OR "3rd wave" OR "third wave" OR "third-wave")
The reference lists of all included studies were searched for other relevant studies. Papers which cited included studies were also checked. Corresponding authors of included studies and other known research groups working in the field were contacted for information regarding unpublished or ongoing trials.

1.3.2 Study inclusion

Studies had to meet the following inclusion criteria:

1) Participants had to be adults who had been diagnosed with functional neurological symptoms, which would fit with diagnostic criteria for functional neurological disorder (FND). That is, clusters of symptoms which present as a neurological condition but for which there has been no identified organic basis for the symptoms experienced. This included a range of disorders which included functional motor disorders, non-epileptic seizures, functional speech disorders and functional dizziness. Although there are similarities between functional neurological disorders and other conditions with medically unexplained symptoms, such as chronic fatigue syndrome, headache and chronic pain, this review focused on conditions defined by clusters of functional neurological symptoms only, as included in pervious reviews (Hopp and LaFrance 2012; Ludwig et al. 2018). Therefore studies of more general ‘medically unexplained symptoms’ were excluded. Studies with subgroups of patients who met the criteria for FND were, however, included if separate data on FND participants could be obtained.

2) The studies had to be intervention studies where the treatment used was based on CBT, including studies of what have been termed ‘third-wave’ CBT interventions (Öst 2008). Interventions were assessed to identify whether they contained key components of CBT, specifically both cognitive and behavioural elements. Studies where participants received additional treatment alongside CBT were included but were highlighted as such within the review.

3) Studies had to have a sample size of five or more to be included. Single-case studies were excluded.

4) As the primary outcome being investigated are daily functioning (defined as general functioning across social, occupational and practical tasks), and secondary outcomes are functional neurological symptoms, anxiety and depression symptoms, studies had to report on a structured assessment of one or more of these areas.

Figure 1.1 shows the flow of study inclusion. Screening was completed by the lead author and any studies where it was unclear whether inclusion criteria were met were discussed within the research team.
1.3.3 Data extraction

The lead author extracted data from all studies which met inclusion criteria, and data from a random 25% sample of these were extracted by an independent researcher to ensure reliability (Kappa=0.91, indicating strong agreement). Data were extracted onto standard forms. Extracted information included study design; intervention design, setting and duration; information for quality assessment; sample size and attrition rates; number of intervention
groups and intervention/control details; outcome measures used; time points for data collection; and main findings.

The Effective Public Health Practice Project (EPHPP) quality assessment tool (Thomas et al. 2004) was used to assess the methodological quality of each study. Studies were not excluded from the review on the basis of methodological quality. However, only studies deemed to be of ‘moderate’ or ‘strong’ methodological quality were included in the meta-analysis, in order to reduce the potential effects of bias. This is covered further in section 1.4.4.

1.3.4 Meta-analysis

Where data were available, means and standard deviations were used to calculate both independent groups and repeated measures effect sizes in order to conduct random effects meta-analyses using the Cochrane Collaboration’s RevMan software (v5.3). Effect sizes as reported in papers were not included in meta-analysis. Consistency was measured using the I² statistic and publication bias was assessed using funnel plots (Appendix I). As the number of studies included in each meta-analysis was fewer than ten, a formal Egger’s test (Egger et al. 1997) was not used (Higgins and Green 2011).

For independent groups, Hedge’s g was calculated for each measure relating to primary or secondary outcomes, along with an estimate of standard error, using the following equations:

Effect size \( (g) = (M_t - M_c) / SD_{pooled} \)

\( M_t \) and \( M_c \) refer to the means of the treatment and control groups respectively and \( SD_{pooled} \) is the pooled SD of both the treatment and control groups using the following equation where \( n_t \) and \( n_c \) are the sample size of the treatment and control groups and \( sd_t \) and \( sd_c \) are the SDs of each group.

\[ SD_{pooled} = \sqrt{\left(\frac{n_t - 1*sd_t^2 + n_c - 1*sd_c^2}{n_t + n_c - 2}\right)} \]

The standard error of the effect size was calculated using the following equation where \( n_t \) and \( n_c \) are the sample sizes of the treatment and the control groups.

\[ SE(g) = \sqrt{\left(\frac{n_t + n_c}{n_t \times n_c}\right) + \left(\frac{g^2}{2(n_t + n_c - 2)}\right)} \]

For repeated measures, Cohen’s d was calculated using the equation:

Effect size \( (d) = \frac{M_{post} - M_{pre}}{SD_{pre}} \)

\( M_{post} \) is the post-treatment mean, \( M_{pre} \) is the pre-treatment mean, and \( SD_{pre} \) is the pre-treatment SD. As \( r \) statistics were not available, standard error was calculated using the equation above, as described in a recent meta-analysis (Hirst et al. 2018). In this equation, \( n_t \) and \( n_c \) were replaced by the number of observations of the treatment group, giving:

\[ SE(d) = \sqrt{\left(\frac{n_t + n_c}{n_t \times n_c}\right) + \left(\frac{d^2}{2(n_t + n_c - 2)}\right)} \]
Different measures were included within each overall outcome effect size. However, where possible, sensitivity analyses were performed with a single measure, in order to determine the validity of this approach.

1.4 Results

1.4.1 Corpus of studies

Table 1.1 shows summary characteristics of the 28 studies included in the review. Nine were described as randomised controlled trials, two were controlled trials, 11 were uncontrolled cohort studies (two retrospective), one was a case-control study and five were case series (two retrospective). A total of 1010 participants were included across the 28 studies, with a sample size range of 6-127, and a mean of 37 (SD=28).

1.4.2 Target of intervention

As shown in Table 1.1, ten studies only included people with non-epileptic seizures (NES), whereas one included a split sample with 63% NES and 37% other functional neurological symptoms, such as limb weakness (Conwill et al. 2014). Three studies included only those with functional motor disorder (FMD), such as limb weakness, paralysis or stiffness. Eight studies included those with functional dizziness, and two included participants with functional dysphonia. A further six studies included participants with a range of functional neurological symptoms.

1.4.3 Type of intervention

The design, content, setting and timescale of interventions varied widely between the studies. CBT interventions are described in Table 1.1, with the main treatment groups including manualised CBT, CBT enhanced with other therapies, CBT-based psychoeducation, CBT-based guided self-help, and CBT-based multidisciplinary inpatient programs, which included input from physiotherapists, occupational therapists and psychiatrists, as well as psychologists. Five studies used so called “third-wave” interventions based on a cognitive behavioural approach; one used dialectical behaviour therapy, two used Acceptance and Commitment Therapy (ACT), one used Mindfulness-Based Psychotherapy (MBPT), and another used a combination of Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT).

Eight of the interventions were delivered in a group format, whereas 14 were delivered on an individual outpatient basis. Six interventions were delivered in an inpatient setting, as a CBT-based multidisciplinary approach. Two of these inpatient programs were for FMD, three for any FND and one for NES. Therapist contact time ranged from a total of two hours over
three months, as part of a guided self-help program (Sharpe et al. 2011) to an intensive inpatient program with a median length of 101 days (McCormack et al. 2014). Timescales and therapeutic contact time for each study is summarised in Table 1.1.
<table>
<thead>
<tr>
<th>Author</th>
<th>Design</th>
<th>Target disorder (^a)</th>
<th>Description of Intervention</th>
<th>Control Group</th>
<th>Sample size and attrition rate</th>
<th>Outcome measures and timepoints (^a)</th>
<th>Main Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andersson et al. (2006)</td>
<td>RCT</td>
<td>Dizziness (mixed functional and organic)</td>
<td>Group combined CBT and vestibular rehabilitation: Five sessions of 60-120 minutes over seven weeks.</td>
<td>Waitlist control group</td>
<td>n=29 (of which 14 had functional dizziness): CBT group=14, control group=15</td>
<td>Baseline and post-treatment: DHI, VSS, CEA, STAI, BDI, PSS, balance measures, symptom diary</td>
<td>Significant benefit of CBT over control on post-treatment on DHI (Cohen's d=.40) and VSS (d=.44). Differences between functional and organic disorder not explored.</td>
</tr>
<tr>
<td>Barrett-Naylor et al. (2018)</td>
<td>Case series</td>
<td>NES</td>
<td>Guided self-help ACT intervention over six weeks, with weekly telephone support.</td>
<td>None</td>
<td>n=7 (6 completers)</td>
<td>Baseline, post-treatment, 1-week and 1-month follow-ups: DASS-21, QOLIE-10, CompACT, AAQ-II, seizure frequency</td>
<td>Reliable and clinically significant positive change on compACT, DASS, QOLIE and seizure frequency for four participants.</td>
</tr>
<tr>
<td>Baslet et al. (2015)</td>
<td>Case series</td>
<td>NES</td>
<td>Individual mindfulness-based psychotherapy: Twelve weekly or biweekly sessions.</td>
<td>None</td>
<td>n=6</td>
<td>Baseline and post-treatment: BDI, DASS, NES frequency</td>
<td>No significant differences. Mean diff in NES frequency per week = 14.98 (18 at baseline to 2.67 at follow-up)</td>
</tr>
<tr>
<td>Best et al. (2015)</td>
<td>Case-control</td>
<td>Somatoform vertigo and dizziness</td>
<td>Group CBT-based intervention: Weekly 90-minute sessions over 10 weeks.</td>
<td>Age and gender matched healthy controls</td>
<td>n=45: 17 cases (13 completers) and 28 matched controls</td>
<td>Baseline and post-treatment: Static posturography, VHQ</td>
<td>Statistically significant improvements in postural control at post-treatment compared to baseline.</td>
</tr>
<tr>
<td>Bullock et al. (2015)</td>
<td>Cohort</td>
<td>NES</td>
<td>Group DBT-skills training: 3 modules, each 8-10 weeks long, comprising weekly 90-minute sessions.</td>
<td>None</td>
<td>n=21 (19 completers)</td>
<td>Baseline and post-treatment: NES frequency, skills diary cards. Baseline only: demographics</td>
<td>No significant differences. Mean diff in frequency per week = 9.1 (13.8 at baseline to 4.7 at 20/5 weeks (average intervention duration))</td>
</tr>
<tr>
<td>Author</td>
<td>Design</td>
<td>Target disorder</td>
<td>Description of Intervention</td>
<td>Control Group</td>
<td>Sample size and attrition rate</td>
<td>Outcome measures and timepoints</td>
<td>Main Findings</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------</td>
<td>-----------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>--------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Chen et al. (2014)</td>
<td>Pilot RCT</td>
<td>NES</td>
<td>Group CBT-based psychoeducation: One 90-minute session per month, over three months following diagnosis of NES.</td>
<td>Treatment as usual control group</td>
<td>n=64: Intervention group=34 (20 completers), Control group=30 (23 completers)</td>
<td>3 months post-diagnosis (post-treatment; T1) and 6 months post-diagnosis (T2): WSAS, NES frequency, NES intensity</td>
<td>Significantly better scores on WSAS in intervention group compared to control at T1 (d=0.81, 95% CI=0.19-1.43; p=0.013) and T2 (d=0.68, 95% CI=0.06-1.32; p=0.038)</td>
</tr>
<tr>
<td>Conwill et al. (2014)</td>
<td>Cohort</td>
<td>NES and other FNS</td>
<td>Group CBT-based therapy: 1 hour per week over 4-5 weeks.</td>
<td>None</td>
<td>n=16: 10 NES, 6 other FNS</td>
<td>Baseline and post-treatment: HADS, SF-36, CGI, NES frequency</td>
<td>Significant improvements in the 'emotional well-being' (p=0.04) and 'role limitation due to emotional well-being' (p=0.04) sub scores of SF-36.</td>
</tr>
<tr>
<td>Cope et al. (2017)</td>
<td>Cohort</td>
<td>NES</td>
<td>Group CBT-based psychoeducation: One 90-minute session per week over three weeks.</td>
<td>None</td>
<td>n=25 (19 completers)</td>
<td>Baseline and post-treatment: frequency of NES, intensity of NES, attitudes, ET7, PHQ-9, GAD-7, WSAS, B-IPQ, DES-II</td>
<td>Significant improvements in time on ET7 (t = 2.42, p=0.028; d=0.38) and BIPQ (t=4.43, p&lt;0.001; d=0.54)</td>
</tr>
<tr>
<td>Dallocchio et al. (2016)</td>
<td>Pilot RCT</td>
<td>FMD</td>
<td>3 arms: Twelve-week intervention of CBT (90-minute session once a week) vs CBT plus APA (60-minute session twice a week) vs control</td>
<td>Waitlist treatment as usual (TAU) control group</td>
<td>n=37: CBT group=14 (11 completers), CBT &amp; APA group=15 (10 completers), TAU control = 8</td>
<td>Baseline and post-treatment: PMDRS, HDS, BAI, PHQ-15</td>
<td>Significant improvement on all outcomes over time for both active groups (all p &lt; 0.001) but not for the control group. Significant differences between CBT and TAU and CBT+APA and TAU at follow-up on all measures (p&lt;0.001).</td>
</tr>
<tr>
<td>Author</td>
<td>Design</td>
<td>Target disorder</td>
<td>Description of Intervention</td>
<td>Control Group</td>
<td>Sample size and attrition rate</td>
<td>Outcome measures and timepoints</td>
<td>Main Findings</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>-------------------------------</td>
<td>--------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Daniilidou et al. (2007)</td>
<td>Consecutive cohort</td>
<td>Functional dysphonia</td>
<td>Individual CBT-enhanced voice therapy: Six weekly 60-minute sessions.</td>
<td>Voice therapy</td>
<td>n=32: CBT-enhanced group=16 (13 completers), control group=16 (15 completers)</td>
<td>Baseline and post-treatment: GRBAS, VPQ, VoiSS, HADS, GHQ</td>
<td>Significant benefit of CBT over control at post-treatment on GHQ (p=.022). Both groups improved significantly over time on VoiSS, VPQ and GHQ. CBT group significantly improved over time on GRBAS and HADS depression.</td>
</tr>
<tr>
<td>Deary et al. (2018)</td>
<td>Pilot RCT</td>
<td>Functional dysphonia</td>
<td>Individual CBT-enhanced voice therapy: 6-8 fortnightly sessions lasting 60-minutes each.</td>
<td>Voice therapy</td>
<td>n=74: CBT group=37 (33 completers), control group=37 (33 completers)</td>
<td>Baseline and follow-up: GRBAS, HADS, VPQ, GHQ</td>
<td>CBT found to be feasible and acceptable. Both interventions had clinical benefits, but trial was not designed to assess between-group effects.</td>
</tr>
<tr>
<td>Demartini et al. (2014)</td>
<td>Cohort</td>
<td>FND</td>
<td>Multidisciplinary CBT-based inpatient program: 5 days per week over an average of 4 weeks.</td>
<td>None</td>
<td>n=66 (all completed post-treatment, 36 completed 1-year follow-up)</td>
<td>Baseline, post-treatment and 1-year follow-up: HoNOS, COPM, HADS, FQ, PHQ-15, CNSQ, IPQ-R</td>
<td>Clinically significant improvement on COPM and statistically significant improvement on CNSQ (p&lt;0.001), HoNOS (p&lt;0.001), HADS (p=0.004) and PHQ-15 (p&lt;0.001). Improvements maintained at 1-year follow-up.</td>
</tr>
<tr>
<td>Detert &amp; Douglass (2014)</td>
<td>Cohort</td>
<td>Neurological disorders with FND subgroup</td>
<td>Group MBSR/MBCT: 8 weekly 2.5 hour sessions.</td>
<td>None</td>
<td>n=182 enrolled, n=147 completed, n=98 followed-up (FND subgroup n=16)</td>
<td>Baseline and post-treatment: BSI (GSI), PSS</td>
<td>Small significant positive effect of MBSR/MBCT on psychiatric symptoms (d=0.2, p&lt;0.05), and large positive effect on perceived stress (d=1.41, p&lt;0.001).</td>
</tr>
<tr>
<td>Author</td>
<td>Design</td>
<td>Target disorder</td>
<td>Description of Intervention</td>
<td>Control Group</td>
<td>Sample size and attrition rate</td>
<td>Outcome measures and timepoints</td>
<td>Main Findings</td>
</tr>
<tr>
<td>------------------------------</td>
<td>--------------</td>
<td>--------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td>-------------------------------</td>
<td>--------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Edelman et al. (2012); Mahoney et al. (2013)</td>
<td>RCT</td>
<td>Chronic subjective dizziness</td>
<td>Individual CBT: weekly sessions over three weeks</td>
<td>Waitlist control group</td>
<td>n=41: 20 in initial treatment group (all completed)</td>
<td>Baseline, post-treatment and 6-month follow-up: DHI, DSI, SBI, DASS-21</td>
<td>Significant benefit of CBT over waitlist on DHI and SBI (both p&lt;0.001), but not on DASS. Positive changes maintained at 6-month follow-up.</td>
</tr>
<tr>
<td>Goldstein et al. (2004)</td>
<td>Cohort</td>
<td>NES</td>
<td>Individual CBT over 12 weeks: Two-hour session in week one, followed by hour-long weekly or fortnightly session. Carer involvement in 3 sessions.</td>
<td>None</td>
<td>n=20 (16 completers)</td>
<td>Baseline, post-treatment and 6-months: NES frequency, WSAS, fear questionnaire, HADS, employment status, MHLC, IPQ, beliefs</td>
<td>Significant improvement on seizure frequency, WSAS, and control and consequences subscales of IPQ (p&lt;0.01), as well as fear questionnaire, HADS and physical causes IPQ subscale (p&lt;0.05). Changes maintained at 6-months.</td>
</tr>
<tr>
<td>Goldstein et al. (2010)</td>
<td>Pilot RCT</td>
<td>NES</td>
<td>Individual CBT over 12 weeks, with one hour-long weekly or fortnightly session.</td>
<td>Treatment as usual control group</td>
<td>n=66: CBT group=33 (30 completers), SMC control group=33 (29 completers)</td>
<td>Baseline, post-treatment and 6-months: NES frequency, NES freedom, WSAS, HADS, CSRI</td>
<td>Significant differences in seizure frequency, favouring CBT, at post-treatment (d=0.75). Both groups improved in some health service use measures and on the WSAS</td>
</tr>
<tr>
<td>Graham et al. (2018)</td>
<td>Case series</td>
<td>FNS</td>
<td>Individual ACT: one hour per week or fortnight, for up to 8 sessions.</td>
<td>None</td>
<td>n=8</td>
<td>Baseline and post-treatment: WSAS, CORE-10, AAQ-II</td>
<td>Post-treatment improvements on WSAS (d=1.02), CORE-10 (d=1.70) and to a lesser degree on AAQ-II (d=0.77).</td>
</tr>
<tr>
<td>Author</td>
<td>Design</td>
<td>Target disorder</td>
<td>Description of Intervention</td>
<td>Control Group</td>
<td>Sample size and attrition rate</td>
<td>Outcome measures and timepoints</td>
<td>Main Findings</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------------</td>
<td>-----------------</td>
<td>-----------------------------</td>
<td>---------------</td>
<td>------------------------------</td>
<td>---------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Holmberg et al. (2006); Holmberg et al. (2007)</td>
<td>Controlled trial</td>
<td>Phobic postural vertigo</td>
<td>Individual CBT: 8-12 sessions, each lasting between 45 and 120 minutes. Self-administered treatment (dizziness exposure)</td>
<td>n=36; CBT group=18 (16 completers), control group=18 (15 completers)</td>
<td>Baseline, post-treatment and 12-month follow-up: VSS, VHQ, DHI, HADS</td>
<td>Significant benefit of CBT over control on VHQ and HADS at post-treatment (both p&lt;0.01). Significant improvements over time in CBT group on DHI, VHQ and HADS. No significant treatment effects remained after 12 months.</td>
<td></td>
</tr>
<tr>
<td>Kuyk et al. (2008)</td>
<td>Cohort</td>
<td>NES</td>
<td>CBT-based inpatient program: 2-6 months of individual therapy, psychomotor and creative therapy, family therapy and a variety of groups.</td>
<td>None</td>
<td>n=25 (22 completers)</td>
<td>Baseline, post-treatment, 6-month follow-up: NES frequency, SCL-90, BDI, STAI, UCL, SF-36, DISQ</td>
<td>Significant reduction in seizure frequency (d=0.37, p=0.02), maintained at follow-up. Significant improvements also seen on BDI, STAI-trait, UCL-active and DISQ scores (all p&lt;0.05).</td>
</tr>
<tr>
<td>Author</td>
<td>Design</td>
<td>Target disorder</td>
<td>Description of Intervention</td>
<td>Control Group</td>
<td>Sample size and attrition rate</td>
<td>Outcome measures and timepoints</td>
<td>Main Findings</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------</td>
<td>-----------------</td>
<td>----------------------------</td>
<td>---------------</td>
<td>-------------------------------</td>
<td>---------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>LaFrance et al. (2009)</td>
<td>Cohort</td>
<td>NES</td>
<td>Individual CBT: one hour per week, for 12 weeks.</td>
<td>None</td>
<td>n=21 (17 completers)</td>
<td>Baseline, and fortnightly thereafter: NES frequency, CGI, BDI, MHRSD, DTS, DES, BIS, FAD, SCL-90, GAF, OHS, LIFE-RIFT, WoC, QOLIE</td>
<td>Significant reduction in seizure frequency from 17.2-7.1 per week (d=0.44, p=0.001). Significant improvement (p&lt;0.05) on BDI, DTS, BIS, FAD, SCL-90, GAF, OHS, LIFE-RIFT, CGI, QOLIE</td>
</tr>
<tr>
<td>LaFrance et al. (2014)</td>
<td>RCT</td>
<td>NES</td>
<td>Individual CBT: one hour per week, for 12 weeks. 4 arms: CBT vs Sertraline vs CBT and Sertraline vs control</td>
<td>Treatment as usual control group</td>
<td>n=38: CBT=9 (8 completers), Sertraline=9 (9 completers), CBT+Sertraline=10 (10 completers), TAU=10 (7 completers)</td>
<td>Baseline, week 2, week 8, week 16 (post-treatment): NES frequency, BDI, BAI, BIS, DTS, DES, SEP, SCL-90, QOLIE, QOL-BFS, ES, WoC, GAF, HDRS, CGI, LIFE-RIFT</td>
<td>Significant reduction in seizure frequency in CBT group (p=0.01) and CBT+Sertraline group (p=0.008). Significantly greater improvement in CBT group, compared to TAU, on GAF (p=0.03), CGI (p=0.01) and OHF (p=0.002). Significantly greater improvement on OHF in CBT group compared to Sertraline group (p=0.01) and CBT+Sertraline Group (p=0.02).</td>
</tr>
<tr>
<td>McCormack et al. (2014)</td>
<td>Retrospective cohort</td>
<td>FMD</td>
<td>CBT-based inpatient program, with psychology, psychiatry, physiotherapy and occupational therapy. Median length of treatment was 101 days.</td>
<td>None</td>
<td>n=33</td>
<td>Baseline and post-treatment: Mobility, ADLs, MRS</td>
<td>Significant improvement in mobility (p&lt;0.001), ADLs (p=0.002) and MRS (p=0.001) at post-treatment.</td>
</tr>
<tr>
<td>Author</td>
<td>Design</td>
<td>Target disorder</td>
<td>Description of Intervention</td>
<td>Control Group</td>
<td>Sample size and attrition rate</td>
<td>Outcome measures and timepoints</td>
<td>Main Findings</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>-------------------------------</td>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Richardson et al. (2018)</td>
<td>Retrospective case-series</td>
<td>FND</td>
<td>Nocebo Hypothesis CBT delivered in an inpatient setting: 2-4 hours of therapy per day, over an average of 14 days.</td>
<td>None</td>
<td>n=13 (12 completers)</td>
<td>Baseline, post-treatment, 12-26 months follow-up: FIM</td>
<td>10 patients in full remission following treatment. 58% had reliable, significant change on FIM. 67% full remission at follow-up.</td>
</tr>
<tr>
<td>Saifee et al. (2012)</td>
<td>Retrospective case series</td>
<td>FND</td>
<td>Multidisciplinary CBT-based inpatient program: 5 days per week over an average of 4 weeks.</td>
<td>None</td>
<td>n=26</td>
<td>Baseline and post-treatment (retrospectively scored), and current (average 7 years post-treatment): Impact of symptoms, IPQ and WSAS</td>
<td>Significant decrease in 'time bothered by symptoms' between baseline and post-treatment (p=0.019). 58% thought symptoms had improved. Significant improvement on WSAS between baseline and follow-up (p=0.01).</td>
</tr>
<tr>
<td>Schmid et al. (2018)</td>
<td>Controlled trial</td>
<td>Functional dizziness</td>
<td>Group CBT (plus vestibular rehabilitation and psychoeducation): 8 90-minute sessions.</td>
<td>Balance disorder control group</td>
<td>n=32: normal balance=16, balance disorder=16</td>
<td>Baseline and post-treatment: DHI, EuroQol questionnaire, BSI, BCI</td>
<td>Significant improvement in normal balance group on DHI (p&lt;0.001) and BSI (p&lt;0.05), but not in balance disorder group.</td>
</tr>
<tr>
<td>Sharpe et al. (2011)</td>
<td>RCT</td>
<td>FNS</td>
<td>Guided self-help (GSH): CBT self-help manual, plus 4 30-minute guidance sessions over 3 months.</td>
<td>Treatment as usual (TAU) control group</td>
<td>n=127: GSH group=64 (62 completers), TAU group=63 (63 completers)</td>
<td>Baseline, post-treatment and 6-month follow-up: PHQ-15, SF-12, HADS, WI, IPQ (and additionally CGI and CPS at post-treatment only)</td>
<td>Significant improvement in GSH group at post-treatment, compared to TAU, on CGI (p=0.016), CPS (p=0.014), PHQ (p=0.009), WI (p&lt;0.05). Significant benefit of GSH group over TAU at 6-month follow-up on CPS (p=0.014), SF-12 (p=0.008) and HADS anxiety (p=0.028).</td>
</tr>
<tr>
<td>Author</td>
<td>Design</td>
<td>Target disorder</td>
<td>Description of Intervention</td>
<td>Control Group</td>
<td>Sample size and attrition rate</td>
<td>Outcome measures and timepoints</td>
<td>Main Findings</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------</td>
<td>-----------------</td>
<td>-----------------------------</td>
<td>---------------</td>
<td>-------------------------------</td>
<td>--------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Yu et al. (2018)</td>
<td>RCT</td>
<td>Functional dizziness</td>
<td>CBT plus Sertraline vs Sertraline alone. 2 one-hour CBT sessions per week, over 8 weeks.</td>
<td>Sertraline control group</td>
<td>n=91: CBT group=46, Sertraline group=45</td>
<td>Baseline, week 2, week 4, week 8 (post-treatment): DHI, HARS, HDRS</td>
<td>DHI, HDRS and HARS scores significantly improved in both groups following treatment (p&lt;0.001). Significantly greater improvements seen in CBT group, compared to control group, on PHI (p&lt;0.001), HDRS (p=0.005) and HARS (p&lt;0.001).</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- AAQ-II: Acceptance and Action Questionnaire
- ADLs: Activities of Daily Living
- BAI: Beck Anxiety Inventory
- BCI: Balance Control Index
- BDI: Beck Depression Inventory
- B-IPQ: Brief Illness Perceptions Questionnaire
- BIS: Barrett Impulsivity Scale
- BSI: Brief Symptom Inventory
- CEA: Confidence in Everyday Activities Questionnaire
- CGI: Clinical Global Impressions
- CNSQ: The Common Neurological Symptom Questionnaire
- CompACT: The Comprehensive Assessment of Acceptance and Commitment Processes
- COPM: Canadian Occupational Performance Measure
- CORE-10: Clinical Outcomes in Routine Evaluation (10 item)
- CPS: Change in Presenting Symptoms Scale
- CSRi: Client Service Receipt Inventory
- DASS: Depression Anxiety Stress Scales
- DES: Dissociative Experiences Scale
- DHI: Dizziness Handicap Inventory
- DISQ: Dissociation questionnaire
- DSI: Dizziness Symptom Inventory
- DTS: Davidson Trauma Scale
- ET7: Emotional Thermometer Scale
- FAD: Family Assessment Device
- FIM: Functional Independence Measure
- FMD: Functional Motor Disorder
- FMS: Functional mobility scale
- FND: Functional Neurological Disorder
- FNS: Functional Neurological Symptoms
- FO: Fear Questionnaire
- GAD-7: Generalised Anxiety Disorder Assessment
- GAF: Global Assessment of Functioning
- GHQ: General Health Questionnaire
- GRBAS: Perceptual Rating of Voice Quality
- HADS: Hospital Anxiety and Depression Scale
- HARS: Hamilton Anxiety Rating Scale
- HoNOS: Health of the Nation Outcome Scale
- IPQ: Illness Perceptions Questionnaire
- LIFE-RIFT: Longitudinal Interval Follow-Up Evaluation Range of Functioning
- Impaired Functioning
- MHRSD: Modified Hamilton Rating Scale for Depression
- NES: Non-epileptic seizures
- OHS: Oxford Handicapped Scale
- PHQ-9: Patient Health Questionnaire
- PMDRS: Psychogenic Movement Disorder Rating Scale
- PRIME-MD: Primary Care Evaluation of Mental Disorders
- PSS: Perceived Stress Scale
- QOL-BFS: Quality of Life Burden to Family Scale
- QOLIE: Quality of Life in Epilepsy-31
- SBI: Safety Behaviours Inventory
- SCL-90: Symptom checklist-90
- SEP: Side Effects Profile
- SF-12: Short Form health survey (12 item)
- STA: State Trait Inventory
- UCL: Utrecht coping list
- VHQ: Vertigo Handicap Questionnaire
- VPQ: Voice Performance Questionnaire
- VoISS: Voice Symptoms Scale
- VSS: Vertigo Symptom Scale
- WSAS: Work and Social Adjustment Scale
- WI: Whitely Index
- WoC: Ways of Coping
1.4.4 Quality assessment

Using the EPHPP quality assessment tool (Thomas et al. 2004), global ratings of quality were calculated based on the number of areas of bias which received a ‘weak’ rating, with no weak ratings indicating a strong study, one weak rating indicating a moderate study, and two or more indicating a weak study (Table 1.2). As well as using the tool, each study was assessed to determine any aspects of bias which would likely impact on the results if included within meta-analysis, as well as looking at any areas where the tool may not have accurately reflected the quality of studies in this particular population.

One aspect of the tool which had potential to over-state bias was the blinding component. As most studies were using interventions with the aim of improving symptoms, and as patients had to be aware of this in order to consent and participate, blinding was impossible in many cases. Some studies also used participant-rated measures where, although some bias may have been present due to participants being aware of the intervention, this was not outcome assessor bias on the part of the research team. In these cases, the blinding component did not contribute to overall ratings, as noted in Table 1.2, where ratings have been put in parentheses. Overall, six studies were deemed to be of strong quality, six were of moderate quality and 16 were classed as weak.
<table>
<thead>
<tr>
<th>Study</th>
<th>Selection Bias</th>
<th>Design</th>
<th>Confounders</th>
<th>Blinding</th>
<th>Data Collection Methods</th>
<th>Withdrawals and drop-outs</th>
<th>Global Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andersson et al. (2006)</td>
<td>weak</td>
<td>strong</td>
<td>strong</td>
<td>(weak)</td>
<td>strong</td>
<td>weak</td>
<td>weak</td>
</tr>
<tr>
<td>Barrett-Naylor et al. (2018)</td>
<td>moderate</td>
<td>weak</td>
<td>strong</td>
<td>moderate</td>
<td>weak</td>
<td>strong</td>
<td>weak</td>
</tr>
<tr>
<td>Baslet et al. (2015)</td>
<td>moderate</td>
<td>weak</td>
<td>weak</td>
<td>weak</td>
<td>strong</td>
<td>strong</td>
<td>weak</td>
</tr>
<tr>
<td>Best et al. (2015)</td>
<td>weak</td>
<td>moderate</td>
<td>weak</td>
<td>weak</td>
<td>weak</td>
<td>moderate</td>
<td>weak</td>
</tr>
<tr>
<td>Bullock et al. (2015)</td>
<td>strong</td>
<td>moderate</td>
<td>moderate</td>
<td>(weak)</td>
<td>weak</td>
<td>strong</td>
<td>moderate</td>
</tr>
<tr>
<td>Chen et al. (2014)</td>
<td>strong</td>
<td>strong</td>
<td>strong</td>
<td>weak</td>
<td>strong</td>
<td>moderate</td>
<td>moderate</td>
</tr>
<tr>
<td>Conwill et al. (2014)</td>
<td>moderate</td>
<td>moderate</td>
<td>weak</td>
<td>strong</td>
<td>weak</td>
<td>strong</td>
<td>weak</td>
</tr>
<tr>
<td>Cope et al. (2017)</td>
<td>strong</td>
<td>moderate</td>
<td>weak</td>
<td>(weak)</td>
<td>strong</td>
<td>weak</td>
<td>moderate</td>
</tr>
<tr>
<td>Dallocchio et al. (2016)</td>
<td>moderate</td>
<td>strong</td>
<td>strong</td>
<td>moderate</td>
<td>strong</td>
<td>moderate</td>
<td>strong</td>
</tr>
<tr>
<td>Daniilidou et al. (2007)</td>
<td>weak</td>
<td>moderate</td>
<td>strong</td>
<td>moderate</td>
<td>weak</td>
<td>strong</td>
<td>weak</td>
</tr>
<tr>
<td>Deary et al. (2018)</td>
<td>moderate</td>
<td>strong</td>
<td>strong</td>
<td>weak</td>
<td>weak</td>
<td>strong</td>
<td>weak</td>
</tr>
<tr>
<td>Demartini et al. (2014)</td>
<td>strong</td>
<td>moderate</td>
<td>strong</td>
<td>weak</td>
<td>strong</td>
<td>weak</td>
<td>weak</td>
</tr>
<tr>
<td>Detert &amp; Douglass (2014)</td>
<td>strong</td>
<td>moderate</td>
<td>strong</td>
<td>(weak)</td>
<td>strong</td>
<td>weak</td>
<td>moderate</td>
</tr>
<tr>
<td>Edelman et al. (2012)</td>
<td>moderate</td>
<td>strong</td>
<td>strong</td>
<td>weak</td>
<td>strong</td>
<td>moderate</td>
<td>moderate</td>
</tr>
<tr>
<td>Goldstein et al. (2004)</td>
<td>strong</td>
<td>moderate</td>
<td>strong</td>
<td>moderate</td>
<td>strong</td>
<td>strong</td>
<td>strong</td>
</tr>
<tr>
<td>Goldstein et al. (2010)</td>
<td>moderate</td>
<td>strong</td>
<td>strong</td>
<td>(weak)</td>
<td>strong</td>
<td>strong</td>
<td>strong</td>
</tr>
<tr>
<td>Graham et al. (2018)</td>
<td>moderate</td>
<td>weak</td>
<td>weak</td>
<td>(weak)</td>
<td>strong</td>
<td>strong</td>
<td>weak</td>
</tr>
<tr>
<td>Holmberg et al. (2006)</td>
<td>moderate</td>
<td>strong</td>
<td>strong</td>
<td>moderate</td>
<td>moderate</td>
<td>strong</td>
<td>strong</td>
</tr>
<tr>
<td>Jacob et al. (2018)</td>
<td>strong</td>
<td>moderate</td>
<td>weak</td>
<td>(weak)</td>
<td>strong</td>
<td>strong</td>
<td>moderate</td>
</tr>
<tr>
<td>Kuyk et al. (2008)</td>
<td>strong</td>
<td>moderate</td>
<td>weak</td>
<td>weak</td>
<td>strong</td>
<td>weak</td>
<td>weak</td>
</tr>
<tr>
<td>LaFrance et al. (2009)</td>
<td>weak</td>
<td>moderate</td>
<td>strong</td>
<td>moderate</td>
<td>strong</td>
<td>weak</td>
<td>weak</td>
</tr>
<tr>
<td>LaFrance et al. (2014)</td>
<td>weak</td>
<td>strong</td>
<td>strong</td>
<td>moderate</td>
<td>strong</td>
<td>strong</td>
<td>moderate</td>
</tr>
<tr>
<td>McCormack et al. (2014)</td>
<td>weak</td>
<td>moderate</td>
<td>strong</td>
<td>weak</td>
<td>n/a</td>
<td>weak</td>
<td>weak</td>
</tr>
<tr>
<td>Richardson et al. (2018)</td>
<td>weak</td>
<td>weak</td>
<td>weak</td>
<td>weak</td>
<td>moderate</td>
<td>strong</td>
<td>weak</td>
</tr>
<tr>
<td>Saifee et al. (2012)</td>
<td>strong</td>
<td>weak</td>
<td>strong</td>
<td>(weak)</td>
<td>weak</td>
<td>n/a</td>
<td>weak</td>
</tr>
<tr>
<td>Schmid et al. (2018)</td>
<td>weak</td>
<td>strong</td>
<td>weak</td>
<td>moderate</td>
<td>strong</td>
<td>weak</td>
<td>weak</td>
</tr>
<tr>
<td>Sharp et al. (2011)</td>
<td>moderate</td>
<td>strong</td>
<td>strong</td>
<td>(weak)</td>
<td>strong</td>
<td>strong</td>
<td>strong</td>
</tr>
<tr>
<td>Yu et al. (2018)</td>
<td>strong</td>
<td>strong</td>
<td>strong</td>
<td>weak</td>
<td>strong</td>
<td>weak</td>
<td>weak</td>
</tr>
</tbody>
</table>
1.4.5 Outcomes

A summary of main findings is included in Table 1.1. Most studies used outcome measures at baseline and post-treatment, with ten studies additionally following-up participants between six months and seven years post-treatment.

Twelve of the 28 studies were rated as being of ‘moderate’ or ‘strong’ quality and were therefore eligible to be included in meta-analysis. However, suitable data were not available in three of the twelve studies. Nine studies (Chen et al. 2014; Cope et al. 2017; Dallocchio et al. 2016; Edelman et al. 2012; Goldstein et al. 2010; Goldstein et al. 2004; Holmberg et al. 2006; LaFrance et al. 2014; Sharpe et al. 2011) were therefore included in meta-analyses, and pre-post effect sizes for the intervention group were calculated for each. Seven of the included studies had a control group, allowing post-intervention effect sizes to be calculated between treatment and control groups, excluding any measures with baseline differences between groups. Funnel plots did not show any evidence of publication bias.

1.4.5.1 Daily functioning

Twenty-one of the 28 studies used a measure of daily functioning or functional impairment. The Work and Social Adjustment Scale (WSAS) was the most commonly used measure of functioning, used in six studies.

Between-group analysis

Effect sizes between CBT and control groups at post-treatment were calculated for the seven controlled studies. Significant heterogeneity was seen ($I^2=55\%$), with two studies reporting larger effect sizes. Even after these were removed in a sensitivity analysis (reducing $I^2$ to 0%), a significant positive effect of CBT was seen over control ($g=-0.44$, 95% CI $-0.66$, -0.22, $p<0.0001$; Figure 1.2).

A sensitivity analysis looked at the two studies which used the WSAS as the measure of functioning (Chen et al. 2014; Goldstein et al. 2010), and the significant effect remained ($g=-0.68$, CI $-1.03$, -0.33, $p=0.0002$). However, an additional sensitivity analysis combined the two studies which used the Dizziness Handicap Inventory (DHI; Edelman et al. 2012; Holmberg et al. 2006), and no significant overall positive effect was seen, although the effect size was still in the small-medium range ($g=-0.34$).
Within-group analysis

In all nine studies included in meta-analysis, repeated measures effect sizes were calculated for daily functioning. However, significant heterogeneity was found ($I^2=66\%$). Three outliers were identified, all with larger effect sizes, and removed from the analysis. A significant effect of CBT over time was seen on measures of functioning ($d=-0.50$, CI -0.76, -0.24, $p=0.0002$; Figure 1.3), a similar sized effect as that seen in the between-groups comparison. A sensitivity analysis including studies which used the WSAS again showed a significant benefit of CBT over time ($d=-0.64$, CI -0.90, -0.37, $p<0.00001$), as did the two studies which used the DHI ($d=-0.99$, CI -1.69, -0.29, $p=0.006$).

1.4.5.2 Functional neurological symptoms

Functional neurological symptoms were measured as an outcome in all studies. The ten NES studies used frequency of attacks as a key outcome. In FMD studies, measures of movement disorder type (tremor, dystonia etc.), mobility, and use of aids were used. In functional dizziness studies, dizziness symptoms and balance measures were used. Of the nine studies of good methodological quality, four reported data on functional neurological symptoms which could be used in meta-analysis, all of which had control groups. As the
other five studies reported NES frequency as an outcome, these were not included due to the data not having normal distribution.

**Between-group analysis**

The four controlled studies had significant heterogeneity when combined ($I^2=92\%$). However, when an outlier with a large effect size was removed, a significant effect of CBT over control remained ($g=-0.30$, CI: -0.56, -0.03, $p=0.03$; Figure 1.4).

![Figure 1.4 Forest plot of the post-intervention effect of CBT on functional neurological symptoms, compared to control](image)

**Within-group analysis**

Data from four studies were used to calculate within-groups effect sizes. Significant heterogeneity was again present ($I^2=94\%$), and when an outlier with a larger effect size was removed, an overall significant positive effect of CBT over time was found ($g=-0.56$, CI: -0.98, -0.13, $p=0.01$; Figure 1.5).

![Figure 1.5 Forest plot of the pre-post effect sizes of CBT on functional neurological symptoms](image)

### 1.4.5.3 Anxiety and depression symptoms

Measures of mood and anxiety were used in 13 studies. These varied between studies, with the Hospital Anxiety and Depression Scale (HADS), Hamilton depression rating scale (HDRS), patient health questionnaire (PHQ-9) and Beck Depression Inventory (BDI) used in three or more studies.
Between-group analysis

Five controlled studies reported data which could be used to calculate independent group effect sizes. An additional study (LaFrance et al. 2014) collected data but effect sizes was not calculated for meta-analysis due to baseline differences between groups. Heterogeneity caused by an outlier with large positive effect sizes was seen in both depression (I²=69%) and anxiety (I²=51%) comparisons. After this study was excluded, a significant small positive effect of CBT compared to control was seen on both anxiety symptoms (g=-0.25, CI -0.50, -0.01, p=0.04; Figure 1.6) and depression symptoms (g=-0.26, CI -0.50, -0.02, p=0.03; Figure 1.7).

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Std. Mean Difference</th>
<th>SE</th>
<th>Weight</th>
<th>IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dallalco (2010)</td>
<td>-1.3</td>
<td>0.37</td>
<td>0.00%</td>
<td>-1.69 [2.33, -0.57]</td>
</tr>
<tr>
<td>Eidelman (2012)</td>
<td>-0.62</td>
<td>0.31</td>
<td>16.2%</td>
<td>-0.92 [4.65, 0.59]</td>
</tr>
<tr>
<td>Goldstein (2010)</td>
<td>-0.21</td>
<td>0.26</td>
<td>23.0%</td>
<td>-0.31 [4.72, 0.30]</td>
</tr>
<tr>
<td>Heineberg (2008)</td>
<td>-0.32</td>
<td>0.35</td>
<td>12.7%</td>
<td>-0.22 [4.91, 0.47]</td>
</tr>
<tr>
<td>Sharpe (2011)</td>
<td>-0.36</td>
<td>0.18</td>
<td>48.1%</td>
<td>-0.39 [0.71, 0.91]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td>-0.25 [0.50, -0.01]</td>
</tr>
</tbody>
</table>

Test for overall effect: Z = 2.12 (p = 0.04)

Figure 1.6 Forest plot of the post-intervention effect of CBT on anxiety symptoms, compared to control

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Std. Mean Difference</th>
<th>SE</th>
<th>Weight</th>
<th>IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dallalco (2010)</td>
<td>-1.57</td>
<td>0.35</td>
<td>0.00%</td>
<td>-1.57 [2.26, -0.08]</td>
</tr>
<tr>
<td>Eidelman (2012)</td>
<td>-0.18</td>
<td>0.32</td>
<td>14.4%</td>
<td>-0.16 [6.79, 0.47]</td>
</tr>
<tr>
<td>Goldstein (2010)</td>
<td>-0.19</td>
<td>0.26</td>
<td>21.8%</td>
<td>-0.18 [6.70, 0.32]</td>
</tr>
<tr>
<td>Heineberg (2008)</td>
<td>-0.37</td>
<td>0.34</td>
<td>12.6%</td>
<td>-0.37 [4.93, 0.30]</td>
</tr>
<tr>
<td>Sharpe (2011)</td>
<td>-0.29</td>
<td>0.17</td>
<td>51.0%</td>
<td>-0.26 [4.82, 0.74]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td>-0.26 [0.50, -0.02]</td>
</tr>
</tbody>
</table>

Test for overall effect: Z = 2.14 (p = 0.03)

Figure 1.7 Forest plot of the post-intervention effect of CBT on depression symptoms, compared to control

Within-group analysis

Eight studies reported repeated-measures data on anxiety and depression symptoms. High but not significant heterogeneity was seen in the anxiety analysis (I²=47%), but an overall significantly positive effect of CBT over time was seen on anxiety symptoms (d=-0.59, CI -0.87, -0.31, p<0.0001; Figure 1.8). When two outliers with larger effect sizes were removed in a sensitivity analysis, the significant effect remained (d=-0.41, CI -0.62, -0.19, p=0.0002). In analysis of depression symptoms, significant heterogeneity was observed due to one outlier with a large effect size (I²=83%). When this as removed, a significantly positive effect of CBT over time was seen (d=-0.37, CI -0.61, -0.13, p=0.002; Figure 1.9). Effects remained
in a sensitivity analysis when only the four studies which had used the most common measure of anxiety and depression symptoms, the HADS, were included.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Std. Mean Difference</th>
<th>SE</th>
<th>Weight</th>
<th>Std. Mean Difference IV, Random, 95% CI</th>
<th>Std. Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cepe et al. (2017)</td>
<td>-0.72</td>
<td>0.32</td>
<td>11.0%</td>
<td>-0.22 [-0.85, 0.41]</td>
<td>-0.22 [-0.85, 0.41]</td>
</tr>
<tr>
<td>Dellicitto et al. (2012)</td>
<td>-1.32</td>
<td>0.25</td>
<td>15.4%</td>
<td>-1.32 [-2.01, -0.63]</td>
<td>-1.32 [-2.01, -0.63]</td>
</tr>
<tr>
<td>Edelman et al. (2004)</td>
<td>-0.69</td>
<td>0.20</td>
<td>12.5%</td>
<td>-0.69 [-1.25, -0.11]</td>
<td>-0.69 [-1.25, -0.11]</td>
</tr>
<tr>
<td>Oelzschus et al. (2010)</td>
<td>-0.44</td>
<td>0.34</td>
<td>1.0%</td>
<td>-0.44 [-1.07, 0.27]</td>
<td>-0.44 [-1.07, 0.27]</td>
</tr>
<tr>
<td>Holmberg et al. (2003)</td>
<td>-0.53</td>
<td>0.25</td>
<td>11.1%</td>
<td>-0.53 [-1.16, 0.12]</td>
<td>-0.53 [-1.16, 0.12]</td>
</tr>
<tr>
<td>LaFrance et al. (2014)</td>
<td>-1.35</td>
<td>0.36</td>
<td>3.5%</td>
<td>-1.35 [-2.25, -0.41]</td>
<td>-1.35 [-2.25, -0.41]</td>
</tr>
<tr>
<td>Sharpe et al. (2011)</td>
<td>-0.44</td>
<td>0.16</td>
<td>19.1%</td>
<td>-0.44 [-0.79, 0.00]</td>
<td>-0.44 [-0.79, 0.00]</td>
</tr>
</tbody>
</table>

Total (95% CI) 100.0% -0.59 [-0.87, -0.31] (d=0.07, CI=12.29, df=7 (P = 0.007), P= 47% Test for overall effect: Z = 4.12 (P = 0.001)

**Figure 1.8** Forest plot of the pre-post effect sizes of CBT on anxiety symptoms

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Std. Mean Difference</th>
<th>SE</th>
<th>Weight</th>
<th>Std. Mean Difference IV, Random, 95% CI</th>
<th>Std. Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cepe et al. (2017)</td>
<td>-0.73</td>
<td>0.31</td>
<td>12.4%</td>
<td>-0.23 [-0.84, 0.38]</td>
<td>-0.23 [-0.84, 0.38]</td>
</tr>
<tr>
<td>Dellicitto et al. (2012)</td>
<td>-2.14</td>
<td>0.29</td>
<td>0.0%</td>
<td>-2.14 [-2.71, -1.57]</td>
<td>-2.14 [-2.71, -1.57]</td>
</tr>
<tr>
<td>Edelman et al. (2004)</td>
<td>-0.77</td>
<td>0.29</td>
<td>13.6%</td>
<td>-0.77 [-1.37, -0.13]</td>
<td>-0.77 [-1.37, -0.13]</td>
</tr>
<tr>
<td>Oelzschus et al. (2010)</td>
<td>-0.98</td>
<td>0.32</td>
<td>11.2%</td>
<td>-0.98 [-2.15, 0.96]</td>
<td>-0.98 [-2.15, 0.96]</td>
</tr>
<tr>
<td>Holmberg et al. (2003)</td>
<td>-0.49</td>
<td>0.33</td>
<td>11.3%</td>
<td>-0.49 [-1.14, 0.16]</td>
<td>-0.49 [-1.14, 0.16]</td>
</tr>
<tr>
<td>LaFrance et al. (2014)</td>
<td>-1.62</td>
<td>0.41</td>
<td>7.6%</td>
<td>-1.62 [-2.62, -0.62]</td>
<td>-1.62 [-2.62, -0.62]</td>
</tr>
<tr>
<td>Sharpe et al. (2011)</td>
<td>-0.69</td>
<td>0.16</td>
<td>28.5%</td>
<td>-0.69 [-0.44, 0.00]</td>
<td>-0.69 [-0.44, 0.00]</td>
</tr>
</tbody>
</table>

Total (95% CI) 100.0% -0.37 [-0.61, 0.03] (d=0.01, CI=1.78, df=6 (P = 0.25), P= 24% Test for overall effect: Z = 0.04 (P = 0.005)

**Figure 1.9** Forest plot of the pre-post effect sizes of CBT on depression symptoms

### 1.4.5.4 Outcomes at follow-up

Six of the studies included in meta-analysis reported six- or twelve-month follow-up data (Chen et al. 2014; Goldstein et al. 2010; Goldstein et al. 2004; Sharpe et al. 2011; Holmberg et al. 2007; Mahoney et al. 2013). Meta-analysis of three controlled studies showed that CBT’s significantly positive effect on functioning, compared to control was strengthened at six-month follow-up (g=−0.57, CI=−0.84, −0.30, p<0.0001). A similar effect size was seen in the CBT groups in five of the six studies between baseline and follow-up, after one outlier was removed due to heterogeneity (d=−0.53, CI=−0.84, −0.21, p=0.001).

Only one study (Sharpe et al. 2011) reported data to calculate an independent groups effect size for functional neurological symptoms at six-month follow-up, which was not significant. However, the significantly positive effect of CBT on functional symptoms over time seen at post-treatment, in meta-analysis of three studies, was strengthened at follow-up (d=−0.61, CI=−1.00, −0.21, p=0.003).
A meta-analysis of effect sizes between CBT and control groups at follow-up for two studies, with non-significant individual effect sizes, found an overall significantly positive effect of CBT for both anxiety symptoms (g=-0.35, CI -0.64, -0.06, p=0.02) and depression symptoms (g=-0.32, CI -0.61, -0.03, p=0.03), larger than immediately following treatment. The effect of CBT at follow-up compared to baseline was calculated for four studies, showing significantly positive change from baseline in both anxiety (d=-0.34, CI -0.58, -0.10, p=0.006) and depression symptoms (d=-0.27, CI -0.51, -0.03, p=0.03).

1.5 Discussion

This systematic review and meta-analysis is the first to explore CBT as an intervention for a wide range of functional neurological symptoms. Overall, based on a small number of high-quality studies, CBT was found to significantly improve daily functioning outcomes, both compared to control groups, and in repeated measures comparisons. CBT also significantly improved functional neurological symptoms, as well as depression and anxiety symptoms. Our findings build on previous reviews which have suggested that psychological interventions are effective for non-epileptic seizures (NES; Gaynor et al. 2014; Carlson and Perry 2017), and that CBT is effective for reducing anxiety, depression and functional symptoms, and improving daily functioning, in those with non-neurological functional symptoms (Jing et al. 2019).

CBT had a significantly positive effect on social and occupational functioning, with effect sizes in the medium range. Effects of this size were seen in both within- and between-groups comparisons, and had slightly increased at follow-up. The effects of CBT on both functional neurological symptoms, and anxiety and depression symptoms were also statistically significant, within the small-medium range. Significantly positive change in anxiety, depression and functional neurological symptoms was maintained at follow-up.

One study was an outlier in most comparisons. This was a pilot RCT with a small sample size investigating CBT as a treatment for functional movement disorders, compared to standard medical care (Dallocchio et al. 2016). The effect sizes calculated from this study were far larger than those seen in other studies, although overall effect sizes were still significant when this study was removed from meta-analyses. This was the only study included in meta-analysis which looked specifically at movement disorders, whereas the rest looked at NES (five studies), functional dizziness (two studies), and mixed functional symptoms (one study). This raises the question of whether CBT for movement disorders may have different effects than in other functional neurological disorders. However, as Dallocchio et al. (2016) is currently the only published RCT of CBT in this population, further research is required to determine whether this is indeed the case.
1.5.1 Limitations

Overall, the methodological quality of studies in this area is mixed, with only nine of the 28 studies included in this review rated as having moderate or strong methodological quality. The main issues across studies were small samples and lack of outcome assessor blinding, leading to considerable risk of bias, and limiting the number of studies which could be combined in meta-analysis. Therefore, only a small number of studies were used to inform estimates of effect, potentially limiting the generalisability of the results.

A limitation was the use of a structured assessment of quality which produced a global rating of bias. In order to ensure that areas of bias were successfully identified, and that overall ratings were accurate, areas of identified bias were assessed further to determine whether they would have an impact on the results if included in meta-analysis. Areas where the tool may not have accurately reflected the quality of studies in this particular population were also investigated further. The tool was adjusted to reflect this, although global ratings were still produced.

In this review, ratings of bias were used to exclude studies from meta-analysis. This in itself may have biased the findings, although the steps outlined above sought to minimise this. Although best practice would be to have included all studies in meta-regression, the high number of poor quality studies would have introduced considerable error into the results and it was decided to exclude these for the purpose of this meta-analysis. However, all studies were included in the review, and a summary of results from these studies were highlighted in Table 1.1.

It should also be noted that there was heterogeneity within study methods. Due to this, different outcome measures were combined within meta-analysis. However, where possible combined effect sizes were compared to specific outcome measures analysed separately, in order to check the validity of this method, and effect sizes were found to be comparable.

1.5.2 Clinical implications

CBT had a significantly positive impact on functioning, functional neurological symptoms, and anxiety and depression symptoms. These differences remained, and were strengthened, at six-month follow-up. This suggests that positive change was maintained, despite participants receiving no further active intervention. Given the high costs associated with healthcare and inability to work in those with FND (Carson et al. 2011), an effective 12-week CBT intervention (such as were those included in this meta-analysis) with lasting positive effects would be an attractive treatment option. However, further research is required to determine whether positive effects persist for longer than six months.

Due to the small number of studies, it was not possible to compare different symptom presentations or types of intervention. However, the aim of this systematic review was
primarily to look at the overall quality of the literature in this area, and assess whether CBT for FND was an intervention that warranted further exploration. There are several studies of CBT for NES with good methodological quality, but further trials for other functional symptoms are required. Overall, all studies identified reported positive outcomes from a CBT-based intervention, suggesting that it is a promising intervention, but further high-quality trials are required.

Future trials would benefit from comparing CBT to treatment as usual, with a long follow-up period in order to assess change over time without intervention. A six- to twelve-month follow-up would also help to determine the lasting effects of any positive change following CBT. Collecting data on social and occupational functioning, and overall emotional wellbeing, would help to determine the impact of CBT on quality of life and disability for those with FND. This is arguably more important as an outcome, for both individuals and services, than a reduction in functional neurological symptoms alone.

1.5.3 Conclusions

CBT is a promising intervention which can improve social and occupational functioning, functional neurological symptoms, and anxiety and depression symptoms in those with FND. These effects persist over time, suggesting CBT could have lasting benefits. However, further high quality and adequately powered trials are required to explore the effectiveness of this intervention further, and to explore any differences between the various FND presentations.
References


Developing a cognitive behavioural understanding of idiopathic drop attacks in the context of functional neurological disorder: a grounded theory study

Emily R. Revell a,b, Jon Stone a, David Gillespie a, Paul G. Morris b

a Department of Clinical Neurosciences, NHS Lothian, Western General Hospital, Edinburgh, EH4 2XU, UK
b Clinical and Health Psychology, School of Health in Social Science, University of Edinburgh, Edinburgh, EH8 9AG, UK

*Corresponding author: Emily R. Revell

Manuscript prepared for submission to Epilepsy & Behavior (https://www.journals.elsevier.com/epilepsy-and-behavior). Author guidelines are included in Appendix C.
2.1 Abstract

Idiopathic drop attacks are falls to the floor, without warning, and without loss of consciousness, for which the cause is uncertain. They are poorly studied but recent research suggests that some drop attacks may be usefully considered as within the spectrum of functional neurological disorder (FND).

The aim of this study was to develop a psychological understanding of idiopathic drop attacks, in order to inform formulation and treatment. Interviews and diaries were completed by seven individuals experiencing drop attacks, and the content of these was analysed using a grounded theory approach.

Predisposing and precipitating factors for idiopathic drop attacks, along with thoughts, emotions and behaviour both before and after a fall, were identified through the coding and synthesis of data into themes. A proposed cognitive behavioural model was identified, with a traumatic first fall and life stressors as predisposing factors. Precipitating factors identified included situational triggers and increased worry. A maintaining cycle of thoughts, emotion and behaviour is outlined.

Our proposed theory overlaps with cognitive behavioural models of functional symptoms, in particular those of non-epileptic seizures. A cognitive behavioural understanding of drop attacks could aid formulation in clinical practice, and suggests that cognitive behavioural therapy interventions for non-epileptic seizures may also be applicable in this population.

**Keywords:** Functional neurological disorder; cognitive behavioural; idiopathic drop attacks; cryptogenic drop attacks; formulation
2.2 Introduction

Idiopathic drop attacks have been defined as falls to the floor without warning, where there is no identified cause, despite comprehensive diagnostic testing to rule out other conditions which can cause drop attacks, such as cardiac, cerebrovascular, vestibular or seizure disorders [e.g. 1, 2]. They are also not caused by malfunction of the lower limbs, or changes in body or head posture [3]. Little research has investigated idiopathic drop attacks, with only two studies exploring them in detail [3, 4], although case studies have also been published [5, 6]. Idiopathic drop attacks have previously been referred to as ‘cryptogenic drop attacks’ [3] or ‘La maladie des genoux bleus’ [5]. In this paper, the term ‘drop attacks’ will be used synonymously with idiopathic or cryptogenic drop attacks.

2.2.1 Prevalence

A recent study surveyed patients with drop attacks presenting to a single neurology clinic over a ten-year period [4]. Eighty-three patients were identified, 89% of whom were female, with a mean age of 44 (range 12-78 years). In a previous study of drop attacks, Stevens and Matthews [3] retrospectively identified 33 patients with drop attacks who had presented to a neurology clinic over a twelve year period, all of whom were female. In their study, onset occurred on average at age 44. The age-range of onset spanned from 19 to 69, but in two thirds of the sample onset was between the ages of 40 and 59. Both studies were conducted within adult services, so it is possible that children are also affected by drop attacks, but no published studies are available to determine this.

Many more women than men present with drop attacks, with women comprising 89-100% of the samples mentioned above. In order to investigate this prospectively in those not presenting specifically to neurology services, Stevens and Matthews [3] approached 100 consecutive male surgery patients to ask if they had ever experienced ‘attacks of unexplained falling’, none of whom had. The authors also asked the same question of 200 consecutive women attending a gynaecological clinic, and found that 3.5% met the criteria for drop attacks. This suggests that this phenomenon could account for a significant number of falls in women in the general population, who may not present to neurology clinics. However, a survey within a general setting attended by both men and women would be required to determine this further, as those presenting to specialist clinics may not be representative of the general population.

2.2.2 Frequency

The frequency of drop attacks varies greatly between individuals. In Hoeritzauer and colleagues’ [4] study, three patterns of attacks were noted: of the 57 patients for whom frequency was reported, 60% experienced regular attacks, which varied between ten per day and one per month, 30% reported single or less frequent attacks, and 10% had clusters
of attacks with periods of freedom from drop attacks between these. However, for 32% of the overall sample, the frequency was not reported. When first seen in clinic, the mean duration of drop attacks was 56 months (range 2-388 months). A similar frequency pattern was seen in the earlier study [3], with 28% having between three and 12 drop attacks per year, 15% having more than 12 falls per year, 45% having two falls or fewer per year, and 12% having clusters of attacks with freedom in between.

### 2.2.3 Associations

Stevens and Matthews [3] reported that falls usually happened while walking (96%), and usually occurred outside of the house, although 43% also had drop attacks inside the house. In Hoeritzauer et al’s [4] sample, 34% of patients could identify triggers for their drop attacks, such as specific places, times or situations where falls would be more likely to occur. Upon direct questioning, 43% of patients described a brief period prior to a drop attack where they would experience feelings of dissociation or depersonalisation.

Hormonal changes were also investigated by Stevens and Matthews [3] as a potential association, given that the age of onset in females frequently coincides with when menopause could be likely to start, and due to the fact that 60% of the younger patients in their sample had onset of drop attacks during pregnancy. However they found no clear links between hormonal changes and drop attacks, although 45% of their sample did experience onset either during pregnancy or within three years either side of the start of the menopause.

### 2.2.4 Impact

Injuries were frequently reported as an outcome of drop attacks. In Stevens and Matthews [3], 93% sustained injuries to their knees, and often also to their hands, chest or face, and 18% reported fractured or broken bones as a result of a drop attack. Hoeritzauer and colleagues [4] noted that 29% of their sample had documented soft tissue injuries following drop attacks, which is likely to be underreported. Of these, 71% had recurrent facial injuries, 50% injured their knees and 9% also reported fractured bones. The authors of both studies reported that many women would become afraid to go out due to both the risk of injury and embarrassment, impacting on their everyday functioning.

### 2.2.5 Mechanism

The underlying mechanism for drop attacks is unclear, due to the lack of research in this area. Other than the two papers mentioned above, the only additional research investigating this group in isolation is a small number of case reports. Butsch and Schneemann [5] reported the cases of two women aged 56 and 79, with recurrent drop attacks while walking, occurring over several years. Another case study identified a 47 year old woman’s drop
attacks as occurring following recollection of traumatic experiences, suggesting a psychological mechanism [6].

It has been suggested that some patients with idiopathic drop attacks can be reclassified within the category of functional neurological disorder [FND; 4], a term which describes neurological symptoms where clinical signs provide positive evidence of a disorder of abnormal nervous system functioning rather than of neurological disease [7]. Functional neurological symptoms are reported to be experienced by 9-30% of those accessing neurology services [8, 9]. Motor ability, speech and vision can all be affected. Some clusters of symptoms, because they are more common, have been grouped together and researched more than others, such as non-epileptic seizures [NES; 10] and functional motor disorders [FMD; 11].

Although there are similarities between drop attacks and NES, drop attacks are not widely included in studies of NES, which tend to focus on events with generalised shaking that superficially resemble epilepsy or events where patients fall down and lie still and unresponsive, superficially resembling syncope. Hubsch et al. [12] analysed clinical signs in 145 NES and identified different subtypes of seizure, none of which covered drop attacks. However, Galimberti et al. [13] and Devinsky et al. [14] included patients with drop attacks within an NES sample, accounting for around 10% of each sample. This suggests that, at least in some cases, drop attacks have significant similarities to NES.

Hoeiritzauer and colleagues [4] developed a hypothesis that drop attacks represent a conditioned behavioural response to negative external (environmental or situational) or internal (anxiety symptoms or dissociation) stimuli. It is proposed that this association is maintained through fear of collapse and/or through the fall providing relief from negative stimuli. This mechanism overlaps with models of NES previously reported in the literature [15, 16].

2.2.6 Therapeutic intervention

Due to the limited literature, there are no recommended evidence-based interventions for drop attacks. However, Hoeiritzauer and colleagues [4] report that for 12% of patients, drop attacks abated following an explanation of the episodes as conditioned responses, and the use of distraction techniques. However, they noted that 51% of their sample had reduced or no drop attacks when followed-up at an average of 38 months and therefore it is unclear how many would have experienced spontaneous resolution.

A better understanding of drop attacks is required to guide both formulation and treatment approaches. Given the potential overlap between drop attacks and other functional symptoms, especially NES, a deeper understanding of drop attacks could help to identify whether psychological interventions which show some efficacy in NES, such as cognitive behavioural therapy [CBT; 17], may also be helpful at reducing falls in this population. A
CBT intervention could also focus on helping individuals to manage their condition and improve the ways they cope with the anxiety surrounding future falls.

2.2.7 Aims

The aim of our study was to explore whether a cognitive-behavioural understanding of drop attacks could help to guide formulation and treatment. This was investigated through the collection of qualitative data from interviews and diaries from individuals experiencing drop attacks. The data were analysed using a grounded theory approach [18] in order to better understand the onset of drop attacks, the impact of life stressors as well as thoughts, feelings and behaviour both directly before and after a drop attack.

The primary research question was as follows:

- What are the predisposing and precipitating factors related to drop attacks?

Secondary research questions were:

- What are individuals’ thoughts, emotions and behaviour immediately prior to a drop attack?
- What are individuals’ thoughts, emotions and behaviour immediately following a drop attack?

2.3 Methods

2.3.1 Participants

Participants were individuals who were experiencing ongoing drop attacks who were recruited from a neurology outpatient clinic at a regional neuroscience unit in Edinburgh, UK (the Department of Clinical Neurosciences, serving a population of approximately 800,000). Inclusion criteria were 1) Diagnosis of idiopathic drop attacks, following assessment and relevant investigations, 2) Aged 18+, 3) Drop attacks occurring 6+ times per year, 4) Able to provide informed consent. Ethical approval (Appendix D) was granted by the South Yorkshire Research Ethics Committee (Reference: 17/YH/0438) and the NHS Lothian Research and Development Office (Reference: 2017/0335). The study protocol (Appendix E) was registered with Clinicaltrials.gov (Reference: NCT03694769).

Due to the relatively small numbers of people diagnosed with drop attacks under the care of the Department of Clinical Neurosciences, approximately eight new diagnoses per year [4], we aimed to recruit a homogenous sample of ten participants. Due to the low numbers of men presenting with drop attacks, an entirely female sample was therefore recruited. In order to maximise data, and the likelihood of approaching saturation, two methods of data
collection were used: interviews and written diaries. All those who had been seen at a single neurology clinic between 2016 and 2018 were screened for eligibility, and contacted if they met inclusion criteria and fit with the sampling method (Figure 2.1).

![Participant flowchart](image)

**Figure 2.1: Participant flowchart**

### 2.3.2 Design

In this exploratory qualitative study, neurology outpatients with ongoing drop attacks underwent a semi-structured interview and completed written diaries for eight weeks. Throughout the study, participants received treatment as usual from their neurologist.

### 2.3.3 Procedure

Participants were approached by their neurologist who gave them a participant information sheet. If they were interested in taking part, a meeting was arranged to discuss the study further and obtain written informed consent. Participants met with the researcher to give consent and complete an hour-long interview. Following this initial interview, participants
were asked to record written accounts of any drop attack that occurred over the subsequent eight weeks during which the researcher contacted them fortnightly by telephone to discuss any difficulties or concerns. If participants did not experience any drop attacks during this period, they were asked if they would be willing to continue keeping a diary for an additional two to four weeks. Participants then met again with the researcher to return the diaries and discuss any reflections that they had about any aspect of the process.

2.3.4 Data collection

2.3.4.1 Semi-structured assessment interview

The audio-recorded interview was semi-structured, with suggested questions designed to facilitate discussion related to the research questions. The interview schedule (see Appendix F) was based on a cognitively-informed clinical interview schedule, and was refined based on factors found previously to be relevant in this population [4], and factors commonly reported in discussions with a neurologist working with patients with drop attacks. The schedule included questions about recent drop attacks, the onset of these and relevant personal and social history. Participants’ experiences of drop attacks were also discussed, focussing on thoughts, feelings and behaviour before and after the episodes. Participants were also asked about the impact that drop attacks had on their everyday functioning.

2.3.4.2 Drop attack diary

Participants were given diaries along with an accompanying prompt sheet (Appendix G) which asked them to record what had happened, along with their thoughts, physical symptoms, feelings and behaviour, as close to the event as possible. They were encouraged to write detailed accounts, outlining the period before, during and after the episode, in order to identify any potential triggers.

2.3.5 Analysis

The content of the interviews and diaries was analysed using a grounded theory approach [18]. Following Charmaz, a constructivist stance was taken, with research questions, based on knowledge of the existing literature, used as a starting point to guide data collection. The constructivist approach also acknowledges the influence of the researcher in the collection and interpretation of research data. As such, critical reflexivity throughout the research design, data collection and interpretation process was important. A reflective journal and memo-writing was used throughout this process, documenting any decision making, and the reasons behind these, including assessing the influence of any preconceptions or prior knowledge. The journal was also used to record personal ‘gut feelings’ about the data, in order to assess this for bias, and address the influence of this on the refinement of interview questions and interpretation of data.
Using both interviews and diaries allowed information to be obtained from different viewpoints, enriching the data. Data from both interviews and diaries was coded in three stages. Initial line-by-line open coding of transcripts was completed, followed by focused coding which involved sorting and grouping both frequently occurring codes, and those which were more relevant to the research questions. The third coding stage was theoretical coding. This comprised looking at relationships between codes in order to identify hypotheses which could be integrated into a theory. An excerpt of transcript and codes is included in Appendix H.

Coding was completed as data were collected, allowing refinement and changes to be made over the course of the data collection period. The codes that emerged from the first four interviews, along with memos written alongside these, were used to refine questions used in subsequent interviews. Focused codes and theoretical codes were refined and altered over time, based on information from subsequent interviews and memos.

Several steps were taken to reduce potential bias. Memo-writing was used throughout data collection and analysis, in order to record reflections on the meaning in data and codes, explore connections between data, and outline methodological decision making. Particular focus was given to identifying data which was contrary to emerging themes, and which would not fit with a cognitive-behavioural model, or an understanding consistent with FND. Participants were also invited to review the codes that were identified within their interviews. Any discrepancies were discussed within the research team until consensus was reached.

2.4 Results

Seven participants, all women between the ages of 40 and 71, completed interviews which ranged from 57 to 73 minutes. Three participants also completed diaries of their drop attacks, writing between 250 and 1000 words. Within the eight-week diary period, one participant experienced one drop attack, and another had two drop attacks. The third participant had no drop attacks within the eight-week period and agreed to continue keeping a diary for a further four weeks. She subsequently experienced a cluster of five drop attacks over the four weeks, the first of which was a very painful fall resulting in a hospital visit. Four participants did not complete diaries; two did not have any drop attacks within the prolonged diary period, one was lost to follow-up, and another declined to take part in the diary portion of the research due to the perceived burden of doing so, as she was experiencing multiple drop attacks each day. Most participants preferred to call their drop attacks simply ‘falls’ with one individual also referring to them as ‘drops’. This is reflected in the content below, where these terms are used interchangeably.
2.4.1 Main themes

The three key categories (predisposing, precipitating and maintaining factors) and nine main themes from the interviews and diaries are displayed in Figure 2.2. No new key themes were identified from the final two interviews, suggesting that theoretical saturation was approached [18]. Themes are described in further detail below, grouped by the categories given, and with relevant example quotes.

![Diagram of main categories and themes](image)

Figure 2.2: Main categories and themes

2.4.1.1 Predisposing factors

Table 2.1 shows example quotes illustrating the two main themes which emerged as predisposing factors: prior experience of falling, and life stressors. For all participants, the initial experience of falling was notable in one of two ways. In some, the first falls occurred during a particularly stressful time, and were related to medical reasons, such as low blood pressure, pain, Meniere’s disease or migrainous stroke. In other cases, the first falls themselves were the stressful event, with falls leading to significant injuries or risk to children. In all cases, the falls then continued, with varying courses, despite there no longer being a clear cause or trigger.

Past life stressors were mentioned by all participants who experienced traumatic or stressful experiences in their lives prior to developing drop attacks. Most participants also reported current life stressors including relationship and family difficulties, chronic health difficulties,
caring for family members, and work stress. Only one participant reported no current life stressors, and she did not experience any drop attacks during the course of the study.

Table 2.1: Themes and supporting quotes within the predisposing factors category

<table>
<thead>
<tr>
<th>Themes</th>
<th>Quotes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior experience of falling</td>
<td>P07: “I fell down the stairs, my neighbour was with me, she stayed with me in (place). She stayed along the landing from me and she was with me and she shouted ‘(Name)!’ I slipped and tumbled right down to the bottom and blood was everywhere.”</td>
</tr>
<tr>
<td></td>
<td>P03: “I went down between the kerb and the road and I broke my ankle and then I had a blood clot. And I don’t know if it was the blood clot that I had, because I was out of action for such a long time, and I don’t know if it’s... and then I had to try to learn to walk again because I was frightened to walk because of the pain.”</td>
</tr>
<tr>
<td></td>
<td>P06: “(The first drop was) not long after my migrainous stroke and it was scary. It just, just like the right side of my body wouldn’t do anything. And I couldn’t get up from that one. I was kind of like frozen.”</td>
</tr>
<tr>
<td>Life stressors</td>
<td>P02: “The stress of having my little boys on my own. I worried about having a vertigo attack when they were just going about the house. That was very stressful as well.”</td>
</tr>
<tr>
<td></td>
<td>P05: “When you go through difficult situations, can that make it worse? So I’ve got (daughter) through leukaemia twice. My youngest...who was very unhappy, has gone through severe depression and self-harming.”</td>
</tr>
<tr>
<td></td>
<td>P07: “I had three jobs at one point just to survive...Just to survive, to pay the bills and survive. It’s hard on your own.”</td>
</tr>
<tr>
<td></td>
<td>P06: “My mum’s not been well, so I’ve been having a lot of episodes of things.”</td>
</tr>
</tbody>
</table>

2.4.1.2 Precipitating factors

Table 2.2 shows the main themes in the precipitating factors category: situational triggers, high levels of stress, and dissociation. Participants reported falling in different locations and situations, both outside and in the home. Falling in the home was mentioned less frequently, which may have been due to a lower incidence, or due to under-reporting as these falls tended to be accompanied by less embarrassment. For some, falls were more likely to happen in specific situations, particularly in places where falls had happened before. Stairs and steps were a particularly common place for falls to happen, with five participants describing falls that had happened in these circumstances. It appeared that situational triggers were linked to increased levels of stress, as described in the quote from participant two in Table 2.2.
Five participants identified high levels of stress as a trigger for their drop attacks. ‘Stress’ was the preferred word for participants to describe this feeling, although ‘anxiety’ was also used. For some, it was stress immediately prior to a fall which they noticed was a trigger. For others, they noticed falls were more likely during periods when they had a higher general level of stress. However, stress was not always a factor, with some falls not being linked to stress, as noted in the ‘Fall even when calm’ theme in Table 2.2. Two people who identified stress as a trigger for their falls reported that they also had falls when they were feeling calm. Another participant stated that they did not fall at all during particularly stressful periods but were more likely to have falls in the period following this. For another participant, they had never considered the possibility of a link between stress and their falls and were unsure whether this could be a factor.

‘Detachment-type’ dissociation [19] was identified as another precipitating factor. Four participants reported episodes of dissociation. In some cases, these were linked to falling (as described in quotes in Table 2.2), with participants describing a sense of dissociation either prior to the fall or after they had fallen to the floor. Three participants also described periods of dissociation in everyday life, for example, “I would be sitting and talking to a friend and I would just go. And I remember talking to a friend of mine and she was going further and further back. She wasn’t but she was going further and further back and I had like tunnel vision.” (P05).

Table 2.2: Themes and supporting quotes within the precipitating factors category

<table>
<thead>
<tr>
<th>Themes</th>
<th>Quotes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Situational triggers</td>
<td>P02: “If I’m in a situation like boarding an aeroplane where I’ve had a drop attack before then I can feel myself tensing up and thinking what if I do this again, which in turn probably makes it more likely that it will happen”</td>
</tr>
<tr>
<td></td>
<td>P04: “the majority of times (the fall is) either out the back or coming down the stairs.”</td>
</tr>
<tr>
<td>High levels of stress</td>
<td>P01: “It makes me feel anxious, because I know I’ve got all this happening and all this that needs to be done… but as I said I don’t know if that’s maybe part of why I could be falling”</td>
</tr>
<tr>
<td></td>
<td>P02: “I know definitely that if I get anxious or stressed, that will mean I’m more likely to get an attack.”</td>
</tr>
<tr>
<td></td>
<td>P03: “I do know that if I get stressed, and I get worried about something, I’ll have more falls.”</td>
</tr>
<tr>
<td></td>
<td>P05: “I don’t want to be in a situation where I have to worry about (falling), because that would probably just make it worse. You know, people who have stomach problems, the more you worry about it the worse it gets.”</td>
</tr>
<tr>
<td></td>
<td>P06: “I’ve had a few (falls) but I think that’s because I’ve been stressing myself…”</td>
</tr>
<tr>
<td>Themes</td>
<td>Quotes</td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Fall even when calm</td>
<td>P02: “Although, ones that happen when I’m perfectly calm, I can’t explain these at all.”</td>
</tr>
<tr>
<td></td>
<td>P06: “you could say reduce your stress and then it won’t happen, well it still can. You can be totally stress free and standing washing your dishes and (fall).”</td>
</tr>
<tr>
<td></td>
<td>P04: “What seems to happen is that, if I have a really stressful period, it can be not too bad, but then when the stressful period finishes, that’s me.”</td>
</tr>
</tbody>
</table>

Dissociation

| P02: “It’s like I’m there but I’m not there. It’s somebody talking not to me but to somebody else. And although I can see them and I can hear them, it’s as if I’m away somewhere else if you see what I mean. It’s like a sort of dreamlike situation I’m in.” |
| P05: “It’s hard to separate (the falls) from the dissociation, because the dissociation comes first.” |
| P01: “You know, there’s nothing going on in my head, nothing happening, when I actually fall. Even although I’m thinking this that and the other, when I actually fall, there’s nothing there. When I get up again, I start thinking again.” |

2.4.1.3 Maintaining factors

Table 2.3 contains the themes and subthemes which fall under the maintaining factors category, along with supporting quotes.

Emotional impact

The emotional burden of drop attacks could be conceptualised in two subthemes: embarrassment and depression. All but one participant reported feeling embarrassed after a fall outside the house. Embarrassment was less, or absent, when falls happened within the home, and was mainly linked to falls being witnessed by other people. This theme linked to the ‘trying to cope’ subtheme of ‘avoidance’, where, due to embarrassment, participants reported going out less frequently, or trying to get out of a situation quickly after they had fallen. However, one participant reported no embarrassment when she fell, stating “I’ve really never been embarrassed or anything like that about it.” (P02). She instead preferred to be in places where there were more people around, which provided reassurance.

Five participants described current low mood, often linked to their reduced levels of functioning due to their drop attacks, for example, “If I try to live a more normal life, and I do at times try, I start dropping again and it’s difficult.” (P05). Drop attacks impacted on areas of independence, occupation and caring for children and grandchildren: “After I had been in the (hospital) and stuff, my work wouldn’t take me back because they weren’t insured to have me in the building.” (P04). Some had experienced times where they felt that their quality of life was so poor that they did not feel life was worth living.
**Worry and sense-seeking**

The first of the subthemes captured by this theme was ‘Why is this happening?’ Participants reported having lots of questions about why this was happening to them, compared to other people. They also talked about spending a lot of time trying to work out if there were any patterns or triggers to their falls, with the aim of trying to prevent the falls from happening. Four participants reported feelings of self-blame about the falls, thinking that it was their fault that they were happening, describing themselves as ‘stupid’ and ‘silly’. Four participants described worry as being a factor, both generally in daily life, and specifically around falling. Participants also described worrying about falls becoming worse, about the potential for bad injuries, and about the impact of previous injuries on their health in the future. This worry included ‘catastrophic’ thinking about their falls, contemplating worst case outcomes including death. Two participants reported that thinking about falling made it more likely that they would fall. In some instances, participants linked not thinking about falling to having fewer falls, as described in the quotes from participant one and participant three in Table 2.3. However, this took the form of having something else to attend to, rather than suppressing thoughts which participants did not find to be effective.

**Trying to cope**

Two subthemes were identified within this theme: ‘just get on’ and ‘avoidance’. Six participants reported that the approach they took towards their drop attacks was to ‘just get on’. For some this was a feeling of being resigned to having to cope with drop attacks being a part of their lives, and for others this was more a defiance that they were going to carry on regardless. However, despite trying to manage the impact of drop attacks on their lives, all participants still made adjustments to their lives to help them to live with the falls, either by avoiding certain situations or taking actions to prevent themselves from falling. Five participants reported avoiding certain situations, either due to fear of the response of others, or due to the fear of injury. This included social situations, particular locations such as supermarkets, and places within the home where risk was deemed to be higher, such as the shower. Two participants also stated that they would avoid standing or walking when they felt unsteady, despite this not often being a sensation that they would feel prior to a fall.

**Pain and injury**

All participants discussed sustaining injuries as a result of falls, with injuries to the face and knees most common. Although some participants did report significant injuries, such as broken bones, this was not a frequent result of a fall. One participant who could experience several falls a day, mentioned that she was unsure how she had not been more severely injured, considering she had fallen down the stairs multiple times, stating “I’ve never broke a bone…I don’t understand how I’ve never broke a bone” (P04).

Participants reported that they were not usually injured after every fall, but that existing injuries could make falls more painful. When they were not injured, participants recovered
quickly, and were able to get up off the floor immediately after a fall. However, for two of the participants who experienced dissociation around a fall, they stated that they needed longer to recover, for example, “if I’m on the ground, nobody could have hauled me up because I think that would have made me worse. So what I say to people is if I do drop, just leave me and I’ll come round in my own time.” (P02).

**Table 2.3: Themes and supporting quotes within the maintaining factors category**

<table>
<thead>
<tr>
<th>Themes</th>
<th>Subthemes</th>
<th>Quotes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emotional impact</td>
<td>Embarrassment</td>
<td>P01 (diary): “I felt so embarrassed and it was as quick as I could get up and into my car and drove away. I then felt so stupid and glad that there was no-one around.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P03: “The thing that I worry about is the embarrassment of falling. It’s got to the stage now I don’t care how bad it is after I’ve fallen, it’s just the fact that I’ve fallen and people see me.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P05: “Yeah when someone is helping me and then I’m just mortified and I’m embarrassed because I’ve fallen over.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07: “You do feel embarrassed. I don’t think anybody saw me, that time. But you do feel embarrassed, even though your just by yourself.”</td>
</tr>
<tr>
<td>Depression</td>
<td></td>
<td>P04: “there was one stage when, not for a wee while, but one stage when I was like ‘what’s the point? What’s the point in going on anymore?’”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07: “I just can’t be bothered. Just feeling on a wee bit of a downer.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P06: “(I) don’t want to see anyone, don’t want to do anything.”</td>
</tr>
<tr>
<td>Worry and sense-seeking</td>
<td>‘Why is this happening?’</td>
<td>P03: “Sometimes I keep thinking why does it happen to me? Why can’t somebody else have this? Why is it me that’s got it?”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P06: “It’s also a lot of ‘why me’. Why did I get this? Was I a really cruel person in a previous life?”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P01: “I can’t put my finger on anything that would say why I’m falling.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P02: “I’m trying to fathom out what I’ve been doing or what I’ve eaten or if I’ve overdone things, but I can’t find a common denominator anywhere.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P04: “But it’s just like, it’s mad. How can your body just fall down without any warning?”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P05: “It had been years of me trying to deal with a situation that was a debilitating situation where I thought ‘what is this? Is it my fault? Am I depressed? Am I doing this to...”</td>
</tr>
<tr>
<td>Themes</td>
<td>Subthemes</td>
<td>Quotes</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Worrying about falling</td>
<td>P04: “Standing at the top of a flight of stairs scares the living daylights out of me. I’ll grab my husband and be like ‘take my hand’ and he says ‘you’ll be fine’ but I say ‘you dinnae know that’”</td>
</tr>
<tr>
<td></td>
<td>(cont.)</td>
<td>P03: “There was a space but I kept looking at it and thinking, I’m going to fall and because I thought, I did fall.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P06: “Sometimes when I do have them…I’ve been thinking about them, and I don’t know if that can bring them on”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P01: “If I’ve got something in my head to concentrate on, I might not have a fall, if that’s possible.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P03: “When I’ve got (grandson), and he’s not in his pushchair and we’re talking and I’m holding his hand, I’m fine because I think I’m concentrating so much on him that I’m not thinking (about falling)”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07: “I try to just say ‘oh it doesn’t worry me, it doesn’t worry me’ but I think it really does worry me. Because I’ve had a few bad ones and I don’t want to go through all that again but I just don’t know when it’s going to happen.”</td>
</tr>
<tr>
<td></td>
<td>Trying to cope</td>
<td>P02: “I’m not going to stop going on holidays or doing anything because of it because I feel it would be taking control of me then. So you’ve just got to accept it and just carry on.”</td>
</tr>
<tr>
<td></td>
<td>‘Just get on’</td>
<td>P03: “I go on holiday, I travel a lot and I travel myself as well. I travel all over the world. But I still fall. But I don’t want it to stop me going because, It’s a case of if I don’t go I’m actually giving in to this and I don’t want this to happen.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P04: “Unless I’m going with somebody, I don’t feel secure going somewhere different. And if it’s somewhere I’ve never been before, I’m not going, definitely not.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07: “If I’ve nothing to do, well what’s the point (in going out). And that’s a wee bit piece of mind. Because I’ve only fallen twice in the house, it’s always been outside.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P06: “I think that is why I tend not to go out and do things. Just in case. Even though now I know what (the falls) are, I don’t really want to have them in public.”</td>
</tr>
</tbody>
</table>
### Themes

<table>
<thead>
<tr>
<th>Subthemes</th>
<th>Quotes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain and injury</td>
<td>P01: “It felt as though my back was broken. I got a really excruciating pain.”</td>
</tr>
<tr>
<td></td>
<td>P02: “The worst I’ve had is cracked ribs when I fell on my wooden floor in the house. Apart from that, a bump on the head or something.”</td>
</tr>
<tr>
<td></td>
<td>P03 (diary): “(I) fell against the toilet bowl hit my ribs, hip, shoulder and neck. Also broke my front teeth and couldn’t breathe for a bit. Had to go to hospital.”</td>
</tr>
<tr>
<td></td>
<td>P04: “the amount of times I’ve been in A&amp;E with concussion it’s just unbelievable.”</td>
</tr>
<tr>
<td></td>
<td>P05: “I fell on the wrist that I had broken and my knees and I was in so much pain I could barely walk.”</td>
</tr>
<tr>
<td></td>
<td>P07: “I’ve got black eyes and nose and forehead swollen and fractured my thumb and hurt my ribs and coccyx. I was in agony.”</td>
</tr>
<tr>
<td></td>
<td>P06: “Once I did crack a rib or something, and I did the muscle in between because I fell forward onto…I think it was the table. And that’s the only injury I’ve actually had, other than bruising.”</td>
</tr>
</tbody>
</table>

### 2.4.2 Emergent theory

The proposed grounded theory model of the links between themes and categories is displayed in Figure 2.3 below. The links reported are based on those made by participants in interviews and diaries, however, experiences varied between participants, so not all factors will be relevant for all individuals or for all falls. The experiences that the participants reported were shaped by the research questions which were designed to elucidate potential predisposing and precipitating factors, along with thoughts, feelings and behaviour around drop attacks. The model therefore uses these as a framework to group themes, although it is acknowledged that this may introduce bias into the interpretation.
The proposed theory is that individuals initially had an experience of a traumatic fall, which in most cases was due to factors such as illness or a mechanical fall. The increased stress around this, either due to the stress of the fall, or the stressful life situation that this happened within, led to the belief that falls are dangerous or to be feared. The impact of previous life stressors, particularly those around the period of onset, may have also influenced the development of drop attacks, by raising stress levels more generally, leading to an increase in physiological anxiety symptoms and dissociation.

Figure 2.3: Grounded theory model of idiopathic drop attacks
We propose that there is a maintenance cycle for ongoing drop attacks, whereby external triggers for drop attacks, such as being in a place where a fall has happened before, and/or internal triggers such as increased worry about falling, or general heightened anxiety, lead to higher levels of stress. Individuals have thoughts of ‘why is this happening?’ and increasingly worry about falling. Stress levels and physical arousal become elevated, increasing the risk of a drop attack occurring. Falls frequently result in injury, pain, embarrassment and/or dissociation. This in turn serves to reinforce worries about falling, and leads to rumination about factors that may be causing the falls.

Individuals with drop attacks try to cope with their falls by avoiding places where they feel they are likely to fall, or where the risk of injury from falling is higher. Some also avoid social situations due to the potential for embarrassment. However, the impact this has on their daily functioning contributes to low mood. Avoidance reinforces the belief that falls are dangerous and to be feared, and individuals experience increased stress when they cannot avoid ‘risky’ situations, further increasing the likelihood that they will have subsequent falls. In contrast, another approach to the falls is to ‘just get on’. However, it appeared from our sample that this approach was only taken in certain aspects of life, such as continuing to travel abroad, with all participants making some adjustments to their lives due to drop attacks. For some, ‘just get on’ manifested as resignation to the changes they felt they had to make to reduce their falls.

2.5 Discussion

2.5.1 Integration of findings to existing literature

Overall, our model has significant overlap with a previously hypothesised understanding of drop attacks as a conditioned behavioural response [4]. In this previous model, a mechanical fall or syncope was highlighted as a precipitating factor, and internal and external triggers were outlined, such as high anxiety and specific situations. Maintaining factors were also described, such as avoidance. These factors are all present in the model presented here.

There is considerable overlap between the model outlined in this study, and the functional symptoms literature, and in particular as it relates to non-epileptic seizures (NES). The fear-avoidance model of NES, as reported in a recent paper outlining different theoretical understandings of NES [20] provides a CBT framework used to inform CBT interventions for NES [e.g. 21], and overlaps significantly with our proposed theory. This model outlines catastrophic thinking, fear of seizures, avoidance, and reduced functioning as important maintaining factors, all of which feature in our model. A more recent cognitive model of NES also highlights the role of internal and external cues as precipitating factors, as in our model [22].
Our model also fits with the cognitive behavioural model of health anxiety, which highlights the maintaining factors of safety behaviours, such as avoidance, and excessive worry [23]. A cognitive behavioural model of somatoform disorder [24] describes a theory where an innate tendency towards somatic distress symptoms, along with early adverse experiences predispose an individual to experience increased somatic symptoms. This is further increased through stressful life events, and attention to symptoms. A lack of understanding or explanation for the symptoms increases physical anxiety and attention to symptoms, which become paired through classical conditioning. Avoidance of triggers for symptoms feeds into an operant conditioning cycle of further sensitisation. This in turn becomes a vicious stress maintenance cycle of increased stress and physical symptoms, avoidance and selective attention.

This model of health anxiety has significant overlaps with our proposed model. However, in our model it is a traumatic first fall which predisposes the individual to falling rather than having other symptoms. Hoeritzauer et al. [4] proposed that, in individuals who are vulnerable to developing drop attacks through biological or biopsychosocial factors, an event such as a mechanical trip or fall, or an experience of syncope, can act as a triggering event. Worry about this then leads to a cognitive representation of drop attacks. This is in agreement with a recent perspective on functional symptoms was outlined by Van den Bergh and colleagues [25], based on a review of the functional symptom literature. The authors suggest that functional symptoms are a set of perceptions, based on the brain’s interpretation of information from the body, which is guided by past experience. A cognitive representation of a symptom, which is preconscious in nature, is activated when certain triggers are present, such as physiological stress. This fits with our model, where an experience of one or more falls may have led to the expectation of falling within certain conditions. The idea of a functional symptom developing as a result of a similar physical experience has been highlighted previously [26], for example, with limb weakness often being preceded by an injury [27] or persistent postural-perceptual dizziness (PPPD) being preceded by vestibular disorders [28].

Overall, although there are factors within our model that would be present in those with recurrent mechanical falls, such as avoidance and embarrassment, there are also elements which highlight this as a potential form of FND. Namely, that stress and worry can be precursors to a fall, along with dissociation. Dissociation was a significant theme in our study and is also central to NES. Goldstein and Mellers [29] proposed a model of NES where seizures are described as a dissociative response to arousal, despite a lack of reported general anxiety, with avoidance as a key maintaining factor. This fits within our model and may also help to explain drop attacks which occur without a subjective feeling of stress.

Therefore, our theory appears to fit best with a cognitive behavioural model of functional symptoms, with particular overlap with models of NES. This model may be best understood as a ‘meta-model’, as are other cognitive behavioural models of functional symptoms [24],
whereby individuals’ experiences differ but the model serves as a framework to make sense of their experiences, rather than showing prescriptive pathways.

2.5.2 Methodological limitations

A limitation was that participants were recruited from the clinic of a single neurologist with a special interest in functional neurological disorders, and who often explained drop attacks to patients within a conditioned behavioural framework. To assess possible bias from this, participants were asked what their neurologist’s understanding of their drop attacks was. It transpired that participants had not taken on this understanding, and instead the predominant view was that nobody knows why the falls are happening. However, this potential bias was also held in mind throughout analysis, and particular care was taken to look for codes and themes which were contrary to this.

Due to the fact that data about drop attacks were collected from individuals who had been experiencing falls for a long time, more information was available to inform the maintenance of drop attacks rather than their onset. Future research with individuals who have had a more recent onset would help to develop this part of the model further. However, this is limited by the delay individuals usually experience between first onset and diagnosis, due to referral pathways and the need for diagnostic tests.

Our study included a small sample, although it was homogenous, and theoretical saturation was approached, with no new key themes identified in the final two interviews. Recruitment was carried out in a systematic way but it is possible that those who were willing to engage with a psychologist may not be representative of most of those who have drop attacks, given that those with functional neurological symptoms are often reluctant to engage in psychological treatment [30]. However, only one participant who was approached stated that she was not willing to take part due to previous negative experience of psychology services.

The demographics of our sample fit with those in previous studies of drop attacks [3, 4], but there are others who experience falls who were not captured in this sample, such as men and younger women. Although onset was at a younger age for many participants, their beliefs, contributing factors and life circumstances may have changed significantly and will not be captured in this data. A larger sample would be required to explore this further.

2.5.3 Clinical implications and future research

The themes and links highlighted in this research may help to aid formulation and treatment planning in clinical settings. If a cognitive-behavioural model fits with an individual’s symptoms, it may be that a CBT approach could be beneficial for them. Given the significant overlap between NES and drop attacks, understanding and formulating drop attacks as a form of NES may be beneficial in terms of understanding and treating them. As the unpredictability of drop attacks appeared to increase worry about falling, giving patients a
clear formulation of their falls could help to begin to reduce their worry and anxiety about them, and encourage them to make behavioural changes to reduce their avoidance and improve their daily functioning. Participants also reported feeling very alone with their falls, and some mentioned that they would appreciate contact with others who had similar experiences.

Randomised controlled trials of CBT for NES have shown positive results, reducing seizure frequency and improving daily functioning [17, 31], and a large multicentre randomised controlled trial is currently ongoing [32]. These interventions provide psychoeducation about NES and use CBT techniques to help patients to identify triggers, address thoughts and illness beliefs, develop coping strategies for life stressors, engage in avoided activities, learn seizure control techniques and address low self-esteem, low mood, or anxiety. These techniques would all be relevant within our proposed theory of drop attacks.

It would be beneficial for future research to further explore the spontaneous resolution that some individuals experience and identify factors which potentially contribute to this. This could help to determine optimum treatment approaches. Future research should also focus on identifying individuals who were not included demographically in this sample, such as men and younger women, to see whether their experiences also fit with our model.

2.5.4 Conclusion

Idiopathic drop attacks may be best understood in the category of functional neurological symptoms. Our theory shows significant overlap with cognitive behavioural models of NES and other functional symptoms, and suggests that formulation and treatment within this model may be appropriate for those experiencing drop attacks.
References


LaFrance WC, Jr., Baird GL, Barry JJ, Blum AS, Frank Webb A, Keitner GI, Machan JT, Miller I, Szafarski JP, Consortium NESTT. Multicenter pilot treatment trial for

References


doi:10.1212/WNL.0b013e318228c0c7


doi:10.1016/j.clineuro.2010.05.011

doi:https://doi.org/10.1016/j.jpsychores.2011.07.005


doi:https://doi.org/10.1016/j.neubiorev.2017.01.015


Appendices

Appendix A: Author guidelines for *Neuropsychology Review*
Instruction for Authors

Types of Papers

Review, Editorial, Commentary

Manuscript Standards

Manuscript Submission

Manuscripts submitted to Neuropsychology Review should conform to the style of the American Psychological Association Publication Manual (6th edition: 2010). Neuropsychology Review is an EQUATOR adopter. The EQUATOR network represents a collaboration of researchers and journal editors who aspire to improve accuracy and transparency in research by promoting better reporting standards. Because Neuropsychology Review publishes review articles, the EQUATOR elements most relevant are the PRISMA guidelines for preparation and reporting of systematic reviews and meta-analyses (http://www.equator-network.org/reporting-guidelines/prisma/).

While narrative reviews will still be considered for publication when appropriate, Neuropsychology Review encourages publication of systematic reviews of treatment, intervention and diagnostic validity studies as well as systematic reviews of research relating to scientific questions in all aspects of clinical neuropsychology and behavioral neuroscience. Systematic reviews are enhanced by inclusion of a carefully conducted meta-analysis whenever appropriate. Authors of systematic reviews and meta-analyses submitted to Neuropsychology Review should prepare their manuscripts according to the PRISMA guidelines and include a
PRISMA checklist (http://prisma-statement.org/PRISMA Statement/Checklist.aspx) with manuscript submission. When completing the checklist, authors should consider whether their manuscript requires editing to address all of the reporting requirements.

Neuropsychology Review discourages use of numerical rating scales that assign a single number to rank the quality of studies included in the review. Instead, authors should separately rate or classify individual study quality and risk of bias using established criteria such as those included in the critical appraisal checklists (e.g., randomized controlled trials or diagnostic validity studies (http://www.cebm.net/critical-appraisal/)). For treatment and intervention studies key risk-of-bias criteria include, but may not be limited to, adequacy of randomization, pre-treatment equality of groups, blinding of patients, therapist or person undertaking outcome evaluation, adequacy of follow-up and objectivity in outcome measurement. For diagnostic validity studies, risk-of-bias criteria include representativeness of sampling, full information on the test-to-be-evaluated (the index test) and diagnostic group status (the reference standard) and independent, blinded acquisition of reference and index test information. Other risk of bias criteria may be important in some contexts including commercial or other conflict of interest.

Prior to undertaking their systematic review, authors are encouraged to read the PRISMA Explanation and Elaboration paper (http://www.ncbi.nlm.nih.gov/pubmed/19621070). For authors not familiar with preparation of systematic reviews or the PRISMA guidelines, there are extensive information resources available on the PRISMA website (http://www.prisma-statement.org/).

Authors are encouraged to register their systematic review protocol early in the review process (e.g., PROSPERO), and use the PRISMA extension specifically written for reporting a systematic review protocol (i.e., PRISMA-P (http://www.equator-network.org/reporting-guidelines/prisma-protocols/)).

Authors of narrative reviews that are not based on systematic literature searching should justify in their cover letter and in the body of their manuscript why a systematic review was not feasible or appropriate. Likewise, authors of systematic reviews without meta-analysis should explain in their cover letter and in the body of their manuscript why meta-analysis was not considered appropriate (e.g., reviewed studies were not of sufficient quality).

Authors should avoid use of non-standard abbreviations.

OFFPRINTS

25 offprints of each article will be provided free of charge. Additional offprints can be ordered by means of an offprint order form supplied with the proofs.

MANUSCRIPT SUBMISSION

Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities -- tacitly or explicitly -- at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.
Please note that we require all relevant editable source files to be uploaded from the first revision onward. Failing to submit these source files will cause unnecessary delays in the review and production process.

Title Page

The title page should include:
- The name(s) of the author(s)
- A concise and informative title
- The affiliation(s) and address(es) of the author(s)
- The e-mail address, and telephone number(s) of the corresponding author
- If available, the 16-digit ORCID of the author(s)

Abstract

Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.

Keywords

Please provide 4 to 6 keywords which can be used for indexing purposes.

Text

Text Formatting

Manuscripts should be submitted in Word.
- Use a normal, plain font (e.g., 10-point Times Roman) for text.
- Use italics for emphasis.
- Use the automatic page numbering function to number the pages.
- Do not use field functions.
- Use tab stops or other commands for indents, not the space bar.
- Use the table function, not spreadsheets, to make tables.
- Use the equation editor or MathType for equations.
- Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).

Headings

Please use no more than three levels of displayed headings.

Abbreviations

Abbreviations should be defined at first mention and used consistently thereafter.

Footnotes

Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols. Always use footnotes instead of endnotes.

Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.

REFERENCES

Citation

Cite references in the text by name and year in parentheses. Some examples:

- Negotiation research spans many disciplines (Thompson 1990).
- This result was later contradicted by Becker and Seligman (1996).
- This effect has been widely studied (Abbott 1991; Barakat et al. 1995; Kelso and Smith 1998; Medvec et al. 1999).

Reference list

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.

Reference list entries should be alphabetized by the last names of the first author of each work.

- Journal article

- Article by DOI

- Book

- Book chapter

- Online document

Journal names and book titles should be italicized.

For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list.

EndNote style (zip, 3 kB)

TABLES

- All tables are to be numbered using Arabic numerals.
- Tables should always be cited in text in consecutive numerical order.
- For each table, please supply a table caption (title) explaining the components of the table.
ARTWORK AND ILLUSTRATIONS GUIDELINES

Electronic Figure Submission

Supply all figures electronically.

Indicate what graphics program was used to create the artwork.

For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files are also acceptable.

Vector graphics containing fonts must have the fonts embedded in the files.

Name your figure files with “Fig” and the figure number, e.g., Fig1.eps.

Line Art

Definition: Black and white graphic with no shading.

Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.

All lines should be at least 0.1 mm (0.3 pt) wide.

Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.

Vector graphics containing fonts must have the fonts embedded in the files.

Halftone Art

Definition: Photographs, drawings, or paintings with fine shading, etc.

If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.

Halftones should have a minimum resolution of 300 dpi.
Combination Art

**Group I**
- mGlu1a
- mGlu1β
- mGlu1d
- mGlu1E55
- mGlu5a
- mGlu5b

**Group II**
- mGlu3
- mGlu3A4

**Group III**
- mGlu6a
- mGlu6b
- mGlu7a
- mGlu7b
- mGlu7c
- mGlu7d
- mGlu7e
- mGlu8a
- mGlu8b
- mGlu8c

Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
Combination artwork should have a minimum resolution of 600 dpi.

**Color Art**

Color art is free of charge for online publication.
If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
If the figures will be printed in black and white, do not refer to color in the captions.
Color illustrations should be submitted as RGB (8 bits per channel).

**Figure Lettering**
To add lettering, it is best to use Helvetica or Arial (sans serif fonts).

Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).

Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.

Avoid effects such as shading, outline letters, etc.

Do not include titles or captions within your illustrations.

**Figure Numbering**

All figures are to be numbered using Arabic numerals.

Figures should always be cited in text in consecutive numerical order.

Figure parts should be denoted by lowercase letters (a, b, c, etc.).

If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures.

"A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.

**Figure Captions**

- Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
- Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
- No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
- Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
- Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

**Figure Placement and Size**

Figures should be submitted separately from the text, if possible.

When preparing your figures, size figures to fit in the column width.

For large-sized journals the figures should be 84 mm (for double-column text areas), or 174 mm (for single-column text areas) wide and not higher than 234 mm.

For small-sized journals, the figures should be 119 mm wide and not higher than 195 mm.

**Permissions**

If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

**Accessibility**

In order to give people of all abilities and disabilities access to the content of your figures, please make sure that

- All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)
- Patterns are used instead of or in addition to colors for conveying information (colorblind users would then be able to distinguish the visual elements)
- Any figure lettering has a contrast ratio of at least 4.5:1
Electronic Supplementary Material

Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author’s article, as certain information cannot be printed or is more convenient in electronic form.

Before submitting research datasets as electronic supplementary material, authors should read the journal’s Research data policy. We encourage research data to be archived in data repositories wherever possible.

**Submission**

Supply all supplementary material in standard file formats.
Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.

**Audio, Video, and Animations**

- Aspect ratio: 16:9 or 4:3
- Maximum file size: 25 GB
- Minimum video duration: 1 sec
- Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp

**Text and Presentations**

Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
A collection of figures may also be combined in a PDF file.

**Spreadsheets**

Spreadsheets should be submitted as .csv or .xlsx files (MS Excel).

**Specialized Formats**

Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

**Collecting Multiple Files**

It is possible to collect multiple files in a .zip or .gz file.

**Numbering**

If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.
Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", "... additional data are given in Online Resource 4". Name the files consecutively, e.g. "ESM_3.mpg", “ESM_4.pdf”.

**Captions**

For each supplementary material, please supply a concise caption describing the content of the file.

**Processing of supplementary files**
Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.

**Accessibility**

In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that

- The manuscript contains a descriptive caption for each supplementary material
- Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

**ENGLISH LANGUAGE EDITING**

For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the English language is of sufficient quality to be understood. If you need help with writing in English you should consider:

- Asking a colleague who is a native English speaker to review your manuscript for clarity.
- Visiting the English language tutorial which covers the common mistakes when writing in English.
- Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your review.
- Two such services are provided by our affiliates Nature Research Editing Service and American Journal Experts. Springer authors are entitled to a 10% discount on their first submission to either of these services, simply follow the links below.

**English language tutorial**

Nature Research Editing Service

American Journal Experts

Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or accepted.

If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style before publication.

为便于编辑和评审专家准确评估您稿件中陈述的研究工作，您需要确保您的英语语言质量足以令人理解。如果您需要英文写作方面的帮助，您可以考虑：

- 请一位以英语为母语的同事审核您的稿件是否表达清晰。
- 查看一些有关英语写作中常见语言错误的教程。
- 使用专业语言编辑服务，编辑人员会对英语进行润色，以确保您的意思表达清晰，并识别需要您复核的问题。我们的附属机构 Nature Research Editing Service 和合作伙伴 American Journal Experts 即可提供此类服务。

**教程**

Nature Research Editing Service

American Journal Experts

请注意，使用语言编辑服务并非在期刊上发表文章的必要条件，同时也并不意味或保证文章将被选中进行同行评议或被接受。

如果您的稿件被接受，在发表之前，我们的文字编辑会检查您的文稿拼写是否规范以及文体是否正式。
エディターと査読者があなたの論文を正しく評価するには、使用されている英語の質が十分に高いことが必要とされます。英語での論文執筆に際してサポートが必要な場合には、次のオプションがあります。

・英語を母国語とする同僚に、原稿で使用されている英語が明確であるかをチェックしてもらう。

・英語で執筆する際のよくある間違いに関する英語のチュートリアルを参照する。

・プロの英文校正サービスを利用する。校正者が原稿の意味を明確にしたり、問題点を指摘し、英語の質を向上させます。Nature Research Editing ServiceとAmerican Journal Expertsの2つは弊社と提携しているサービスです。Springerの著者は、いずれのサービスも初めて利用する際には10%の割引を受けすることができます。以下のリンクを参照ください。

英語のチュートリアル
Nature Research Editing Service
American Journal Experts

英文校正サービスの利用は、投稿先のジャーナルに掲載されるための条件ではないこと、また論文審査や受理を保証するものではないことに留意してください。
原稿が受理されると、出版前に弊社のコピー・エディターがスペルと体裁のチェックを行います。

英語のチュートリアル
Nature Research Editing Service
American Journal Experts

・英語原稿の場合、エディターやリビューアが誤りのない文を理解し、問題点を指摘し、英語の質を向上させることを必要とします。特に、非母国語での執筆者は、原稿の文法や文章構造を把握することが重要です。

・矛盾や不一致がないことが求められます。特に、数値や図表の一部が合っていない場合や、引用情報に間違いがある場合は、その部分を修正することが求められます。

・論文の内容と目的に合った、簡潔で明確な表現が求められます。冗長や一部の情報が重複していないか確認することが重要です。

・文献引用が適切で、引用文献の各要素が揃っていることを確認することが求められます。文献引用の形式が一貫していることも重要です。

・倫理的責任

This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of misconduct.

Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the research and its presentation is helped by following the rules of good scientific practice, which include:

uder

The manuscript should not be submitted to more than one journal for simultaneous consideration.
• The submitted work should be original and should not have been published elsewhere in any form or language (partially or in full), unless the new work concerns an expansion of previous work. (Please provide transparency on the re-use of material to avoid the concerns about text-recycling (‘self-plagiarism’).

• A single study should not be split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time (i.e. ‘salami-slicing/publishing’).

• Concurrent or secondary publication is sometimes justifiable, provided certain conditions are met. Examples include: translations or a manuscript that is intended for a different group of readers.

• Results should be presented clearly, honestly, and without fabrication, falsification or inappropriate data manipulation (including image based manipulation). Authors should adhere to discipline-specific rules for acquiring, selecting and processing data.

• No data, text, or theories by others are presented as if they were the author’s own (‘plagiarism’). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks (to indicate words taken from another source) are used for verbatim copying of material, and permissions secured for material that is copyrighted.

• **Important note: the journal may use software to screen for plagiarism.**

• Authors should make sure they have permissions for the use of software, questionnaires/(web) surveys and scales in their studies (if appropriate).

• Authors should avoid untrue statements about an entity (who can be an individual person or a company) or descriptions of their behavior or actions that could potentially be seen as personal attacks or allegations about that person.

• Research that may be misapplied to pose a threat to public health or national security should be clearly identified in the manuscript (e.g. dual use of research). Examples include creation of harmful consequences of biological agents or toxins, disruption of immunity of vaccines, unusual hazards in the use of chemicals, weaponization of research/technology (amongst others).

• Authors are strongly advised to ensure the author group, the Corresponding Author, and the order of authors are all correct at submission. Adding and/or deleting authors during the revision stages is generally not permitted, but in some cases may be warranted. Reasons for changes in authorship should be explained in detail. Please note that changes to authorship cannot be made after acceptance of a manuscript.

Upon request authors should be prepared to send relevant documentation or data in order to verify the validity of the results presented. This could be in the form of raw data, samples, records, etc. Sensitive information in the form of confidential or proprietary data is excluded.

*All of the above are guidelines and authors need to make sure to respect third parties rights such as copyright and/or moral rights.

If there is suspicion of misbehavior or alleged fraud the Journal and/or Publisher will carry out an investigation following COPE guidelines. If, after investigation, there are valid concerns, the author(s) concerned will be contacted under their given e-mail address and given an opportunity to address the issue. Depending on the situation, this may result in the Journal’s and/or Publisher’s implementation of the following measures, including, but not limited to:

If the manuscript is still under consideration, it may be rejected and returned to the author.

If the article has already been published online, depending on the nature and severity of the infraction:
- an erratum/correction may be placed with the article
- an expression of concern may be placed with the article
- or in severe cases retraction of the article may occur. The reason will be given in the published erratum, expression of concern or retraction note. Please note that
retraction means that the article is **maintained on the platform**, watermarked "retracted" and the explanation for the retraction is provided in a note linked to the watermarked article.

The author’s institution may be informed
A notice of suspected transgression of ethical standards in the peer review system may be included as part of the author’s and article’s bibliographic record.

**Fundamental errors**

Authors have an obligation to correct mistakes once they discover a significant error or inaccuracy in their published article. The author(s) is/are requested to contact the journal and explain in what sense the error is impacting the article. A decision on how to correct the literature will depend on the nature of the error. This may be a correction or retraction. The retraction note should provide transparency which parts of the article are impacted by the error.

**Suggesting / excluding reviewers**

Authors are welcome to suggest suitable reviewers and/or request the exclusion of certain individuals when they submit their manuscripts. When suggesting reviewers, authors should make sure they are totally independent and not connected to the work in any way. It is strongly recommended to suggest a mix of reviewers from different countries and different institutions. When suggesting reviewers, the Corresponding Author must provide an institutional email address for each suggested reviewer, or, if this is not possible to include other means of verifying the identity such as a link to a personal homepage, a link to the publication record or a researcher or author ID in the submission letter. Please note that the Journal may not use the suggestions, but suggestions are appreciated and may help facilitate the peer review process.

**COMPLIANCE WITH ETHICAL STANDARDS**

To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.

Authors should include the following statements (if applicable) in a separate section entitled “Compliance with Ethical Standards” when submitting a paper:

- Disclosure of potential conflicts of interest
- Research involving Human Participants and/or Animals
- Informed consent

Please note that standards could vary slightly per journal dependent on their peer review policies (i.e. single or double blind peer review) as well as per journal subject discipline. Before submitting your article check the instructions following this section carefully.

The corresponding author should be prepared to collect documentation of compliance with ethical standards and send if requested during peer review or after publication.

The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. The author will be held responsible for false statements or failure to fulfill the above-mentioned guidelines.

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of a real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. Examples of potential conflicts of interests **that**
are directly or indirectly related to the research may include but are not limited to the following:

- Research grants from funding agencies (please give the research funder and the grant number)
- Honoraria for speaking at symposia
- Financial support for attending symposia
- Financial support for educational programs
- Employment or consultation
- Support from a project sponsor
- Position on advisory board or board of directors or other type of management relationships
- Multiple affiliations
- Financial relationships, for example equity ownership or investment interest
- Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
- Holdings of spouse and/or children that may have financial interest in the work

In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be important to readers should be disclosed. These may include but are not limited to personal relationships or competing interests directly or indirectly tied to this research, or professional interests or personal beliefs that may influence your research.

The corresponding author collects the conflict of interest disclosure forms from all authors. In author collaborations where formal agreements for representation allow it, it is sufficient for the corresponding author to sign the disclosure form on behalf of all authors. Examples of forms can be found here:

The corresponding author will include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form(s),

See below examples of disclosures:

**Funding:** This study was funded by X (grant number X).

**Conflict of Interest:** Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.

If no conflict exists, the authors should state:
Conflict of Interest: The authors declare that they have no conflict of interest.

**RESEARCH INVOLVING HUMAN PARTICIPANTS AND/OR ANIMALS**

1) **Statement of human rights**

When reporting studies that involve human participants, authors should include a statement that the studies have been approved by the appropriate institutional and/or national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach, and demonstrate that the independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study.

If a study was granted exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption and the reasons for the exemption).
Authors must - in all situations as described above - include the name of the ethics committee and the reference number where appropriate.

The following statements should be included in the text before the References section:

**Ethical approval:** “All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (include name of committee + reference number) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”

**Ethical approval retrospective studies**

Although retrospective studies are conducted on already available data or biological material (for which formal consent may not be needed or is difficult to obtain) ethical approval may be required dependent on the law and the national ethical guidelines of a country. Authors should check with their institution to make sure they are complying with the specific requirements of their country.

### 2) Statement on the welfare of animals

The welfare of animals used for research must be respected. When reporting experiments on animals, authors should indicate whether the international, national, and/or institutional guidelines for the care and use of animals have been followed, and that the studies have been approved by a research ethics committee at the institution or practice at which the studies were conducted (where such a committee exists). Please provide the name of ethics committee and relevant permit number.

For studies with animals, the following statement should be included in the text before the References section:

**Ethical approval:** “All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.”

If applicable (where such a committee exists): “All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted (include name of committee + permit number)”

If articles do not contain studies with human participants or animals by any of the authors, please select one of the following statements:

“This article does not contain any studies with human participants performed by any of the authors.”

“This article does not contain any studies with animals performed by any of the authors.”

“This article does not contain any studies with human participants or animals performed by any of the authors.”

### INFORMED CONSENT

All individuals have individual rights that are not to be infringed. Individual participants in studies have, for example, the right to decide what happens to the (identifiable) personal data gathered, to what they have said during a study or an interview, as well as to any photograph that was taken. Hence it is important that all participants gave their informed consent in writing prior to inclusion in the study. Identifying details (names, dates of birth, identity numbers and other information) of the participants that were studied should not be published in written descriptions, photographs, and genetic profiles unless the information is essential for scientific purposes and the participant (or parent or guardian if the participant is incapable) gave written informed consent for publication. Complete anonymity is difficult to achieve in some cases, and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of participants is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic profiles, authors should provide assurance that alterations do not distort scientific meaning.

The following statement should be included:
Informed consent: “Informed consent was obtained from all individual participants included in the study.”

If identifying information about participants is available in the article, the following statement should be included:

“Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.”

AFTER ACCEPTANCE

Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice, offprints, or printing of figures in color.

Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.

Copyright transfer

Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.

Offprints

Offprints can be ordered by the corresponding author.

Color illustrations

Online publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a contribution towards the extra costs.

Proof reading

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.

After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online First

The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

OPEN CHOICE

Open Choice allows you to publish open access in more than 1850 Springer Nature journals, making your research more visible and accessible immediately on publication.

Article processing charges (APCs) vary by journal – view the full list

Benefits:

- Increased researcher engagement: Open Choice enables access by anyone with an internet connection, immediately on publication.
- Higher visibility and impact: In Springer hybrid journals, OA articles are accessed 4 times more often on average, and cited 1.7 more times on average*.
- Easy compliance with funder and institutional mandates: Many funders require open access publishing, and some take compliance into account when assessing future grant applications.

It is easy to find funding to support open access – please see our funding and support pages for more information.
The NeuroNetwork - a professional networ...

Journal Editor E-mail

RELATED BOOKS - SERIES - JOURNALS

Journal
Acta Neurologica Belgica
Editor Editor-in-Chief: Patrick Cras
## Appendix B: PRISMA checklist

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TITLE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Identify the report as a systematic review, meta-analysis, or both.</td>
<td>8</td>
</tr>
<tr>
<td><strong>ABSTRACT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structured summary</td>
<td>2</td>
<td>Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.</td>
<td>9</td>
</tr>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>3</td>
<td>Describe the rationale for the review in the context of what is already known.</td>
<td>10-12</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
<td>Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).</td>
<td>12</td>
</tr>
<tr>
<td><strong>METHODS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol and registration</td>
<td>5</td>
<td>Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.</td>
<td>12</td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>6</td>
<td>Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.</td>
<td>13-14</td>
</tr>
<tr>
<td>Information sources</td>
<td>7</td>
<td>Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.</td>
<td>13</td>
</tr>
<tr>
<td>Search</td>
<td>8</td>
<td>Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.</td>
<td>13</td>
</tr>
<tr>
<td>Section/topic</td>
<td>#</td>
<td>Checklist item</td>
<td>Reported on page #</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>----</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Study selection</td>
<td>9</td>
<td>State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).</td>
<td>13-14</td>
</tr>
<tr>
<td>Data collection process</td>
<td>10</td>
<td>Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.</td>
<td>15-16</td>
</tr>
<tr>
<td>Data items</td>
<td>11</td>
<td>List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.</td>
<td>15-16</td>
</tr>
<tr>
<td>Risk of bias in individual studies</td>
<td>12</td>
<td>Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.</td>
<td>16</td>
</tr>
<tr>
<td>Summary measures</td>
<td>13</td>
<td>State the principal summary measures (e.g., risk ratio, difference in means).</td>
<td>16</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>14</td>
<td>Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$) for each meta-analysis.</td>
<td>16</td>
</tr>
<tr>
<td>Risk of bias across studies</td>
<td>15</td>
<td>Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).</td>
<td>16</td>
</tr>
<tr>
<td>Additional analyses</td>
<td>16</td>
<td>Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.</td>
<td>16</td>
</tr>
</tbody>
</table>

**RESULTS**

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study selection</td>
<td>17</td>
<td>Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.</td>
<td>15</td>
</tr>
<tr>
<td>Study characteristics</td>
<td>18</td>
<td>For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.</td>
<td>17-25</td>
</tr>
<tr>
<td>Risk of bias within studies</td>
<td>19</td>
<td>Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).</td>
<td>26-27</td>
</tr>
<tr>
<td>Results of individual studies</td>
<td>20</td>
<td>For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.</td>
<td>28-33</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>21</td>
<td>Present results of each meta-analysis done, including confidence intervals and measures of consistency.</td>
<td>28-33</td>
</tr>
<tr>
<td>Risk of bias across studies</td>
<td>22</td>
<td>Present results of any assessment of risk of bias across studies (see Item 15).</td>
<td>28</td>
</tr>
<tr>
<td>Section/topic</td>
<td>#</td>
<td>Checklist item</td>
<td>Reported on page #</td>
</tr>
<tr>
<td>-------------------</td>
<td>----</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Additional analysis</td>
<td>23</td>
<td>Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).</td>
<td>28-33</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary of evidence</td>
<td>24</td>
<td>Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).</td>
<td>33-34</td>
</tr>
<tr>
<td>Limitations</td>
<td>25</td>
<td>Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).</td>
<td>34</td>
</tr>
<tr>
<td>Conclusions</td>
<td>26</td>
<td>Provide a general interpretation of the results in the context of other evidence, and implications for future research.</td>
<td>35</td>
</tr>
<tr>
<td>FUNDING</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td>27</td>
<td>Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.</td>
<td>8</td>
</tr>
</tbody>
</table>

Appendix C: Author guidelines for *Epilepsy & Behavior*
DESCRIPTION

*Epilepsy & Behavior* is the fastest-growing international journal uniquely devoted to the rapid dissemination of the most current information available on the behavioral aspects of seizures and epilepsy.

*Epilepsy & Behavior* presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging.

*Epilepsy & Behavior* publishes papers on the study of:

- Localization of ictal and postictal behaviors
- Neuroendocrine aspects of epilepsy
- Psychiatric and psychosocial aspects of epilepsy
- Behavioral aspects of epilepsy surgery
- Cognitive and affective effects of seizure treatment
- Functional imaging
- Animal models

From September 2012 *Epilepsy & Behavior* stopped accepting Case Reports for publication in the journal. From this date authors who submit to *Epilepsy & Behavior* will be offered a transfer or asked to resubmit their Case Reports to its new sister journal, *Epilepsy & Behavior Case Reports*.

As of July 1, 2017, *Epilepsy & Behavior* will no longer accept Letters to the Editor except for those that comment on articles that were previously published in *Epilepsy & Behavior*.

Indexing

Cited in MEDLINE/PubMed and Index Medicus, Current Contents/Clinical Medicine, Science Citation Index-Expanded, NeuroScience Citation Index, PsychINFO, and EMBASE.

AUDIENCE

Researchers in neurology, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging, epilepsy fellows, epileptologists, neurologists, psychiatrists, neurosurgeons, and epilepsy nurses.
IMPACT FACTOR

2017: 2.600 © Clarivate Analytics Journal Citation Reports 2018

ABSTRACTING AND INDEXING

Scopus
PsycINFO
PubMed
ScienceDirect
Google Scholar

EDITORIAL BOARD

Editor-in-Chief
S.C. Schachter *, CIMIT, Harvard University, 165 Cambridge St, Boston, MA 22114, Massachusetts, USA

Associate Editors
C.E. Elger, Clinic of Epileptology, Rheinische Friedrich-Wilhelms-Universität Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany
B. Hermann, Dept. of Neurology, University of Wisconsin at Madison, 1300 University Avenue, Madison, Wisconsin, WI 53706, USA
M. Mula, Atkinson Morley Regional Neuroscience Centre, Epilepsy Group, St. George's Hospital, Blackshaw Road, SW17 0QT, London, England, UK

Founding Associate Editor
O. Devinsky, New York University, New York, USA

Editorial Board
H. Adeli, The Ohio State University, Columbus, Ohio, USA
S. Aminoff Kelley, Johns Hopkins University, Baltimore, Maryland, USA
E. Andermann, Montreal Neurological Hospital and Institute, Québec, Quebec, Canada
F. Andermann, Montreal Neurological Hospital and Institute, Montreal, Quebec, Canada
M. Asato, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, USA
R. Bautista, University of Florida, Jacksonville, Florida, USA
S. Baxendale, University College London (UCL), London, UK
C. Begley, University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA
S.R. Benbadis, University of South Florida and Tampa General Hospital, Tampa, Florida, USA
S. Beniczky, Aarhus University, Aarhus C, Denmark
A.T. Berg, Children's Memorial Hospital, Chicago, Illinois, USA
M.M. Berl, Children's National Health System, Washington DC, Washington, USA
F.M.C. Besag, Bedfordshire & Luton Community NHS Trust, Clapham, Bedford, UK
M. Bialer, Hebrew University of Jerusalem, Jerusalem, Israel
L. Bonilha, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA
F. Brigo, University of Verona, Verona, Italy
M.J. Brodie, Western Infirmary, Glasgow, Scotland, UK
J.G. Burneo, Western University, London, Ontario, Canada
R. Busch, Cleveland Clinic Foundation, Cleveland, Ohio, USA
C. S. Camfield, IWK-Grace Health Centre, Halifax, Nova Scotia, Canada
A.E. Cavanna, University of Birmingham, Birmingham, England, UK
J.E. Cavazos, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA
R. Chin, The University of Edinburgh, Edinburgh, Scotland, UK
F. Drislane, Harvard Medical School, Charlestown, Massachusetts, USA
D.W. Dunn, Indiana University School of Medicine, Indianapolis, Indiana, USA
D.J Englot, Vanderbilt University Medical Center, Nashville, Tennessee, USA
* Members of Targeted Review Committee
P. Fisher, University of Liverpool, Liverpool, UK
N. Garcia-Cairasco, Universidade de São Paulo (USP), Sao Paulo, Brazil
B.E. Gidal, University of Wisconsin at Madison, Madison, Wisconsin, USA
A. R. Giovangoli, National Neurological Institute "Carlo Besta", Milano, Italy
A.C. Grant, SUNY Downstate Medical Center, Brooklyn, New York, USA
A.B. Guekht, Russian National Research Medical University, Moscow, Russian Federation
C.D. Hahn, University of Toronto (Hospital for Sick Children), Toronto, Ontario, Canada
GUIDE FOR AUTHORS

INTRODUCTION

Epilepsy & Behavior has been, and still is, the fastest-growing international journal since its launch in 2000. Epilepsy & Behavior is uniquely devoted to the rapid dissemination of the most current information available on the behavioral aspects of seizures and epilepsy.

Epilepsy & Behavior presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging.

Epilepsy & Behavior publishes papers on the study of:
- Localization of ictal and postictal behaviours
- Neuroendocrine aspects of epilepsy
- Psychiatric and psychosocial aspects of epilepsy
- Behavioral aspects of epilepsy surgery
- Cognitive and affective effects of seizure treatment
- Functional imaging
- Animal models

Types of article

Epilepsy & Behavior publishes the following types of articles:
- Original research articles (both clinical and laboratory research)
- Reviews
- Editorials
- Brief communications
- Letters
- Book reviews
- Calendar of events

Please note: From 1st September 2012 Epilepsy & Behavior will stop accepting Case Reports for publication in the journal. From this date authors who submit to Epilepsy & Behavior will be offered a transfer or asked to resubmit their Case Reports to its new sister journal, Epilepsy & Behavior Case Reports.

Contact details for submission

Authors should submit their articles electronically at: http://ees.elsevier.com/eb.

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address

All necessary files have been uploaded:

Manuscript:
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)

Further considerations
- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
BEFORE YOU BEGIN

**Ethics in publishing**
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

**Studies in humans and animals**
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

**Declaration of interest**
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

**Submission declaration and verification**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

**Preprints**
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior
to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

**Changes to authorship**
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Copyright**
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of existing agreements are available online. After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

**Open access**
This journal offers authors a choice in publishing their research:

**Subscription**
- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.
• No open access publication fee payable by authors.
• The Author is entitled to post the accepted manuscript in their institution’s repository and make this public after an embargo period (known as green Open Access). The published journal article cannot be shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-reviewed research in journal publications. The embargo period for this journal can be found below.

**Gold open access**

• Articles are freely available to both subscribers and the wider public with permitted reuse.
• A gold open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For gold open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)**
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 2850**, excluding taxes. Learn more about Elsevier's pricing policy: https://www.elsevier.com/openaccesspricing.

**Green open access**
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.

This journal has an embargo period of 12 months.

**Elsevier Researcher Academy**
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

**Language (usage and editing services)**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop.

**Submission**
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

**Submit your article**
Please submit your article via http://ees.elsevier.com/eb.

**PREPARATION**
**Peer review**
This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of one independent expert reviewer to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.

**Use of word processing software**
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**Article structure**

**Subdivision - numbered sections**
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

**Introduction**
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

**Material and methods**
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

**Results**
Results should be clear and concise.

**Discussion**
The Discussion section should explore the significance of the results of the work, not repeat them. Results and Discussion should be separate and may be organized into subheadings. Avoid extensive citations and discussion of published literature.

**Conclusions**
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

**Essential title page information**
- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Please note that proprietary names for drugs should *not* be used in the article title.

**Highlights**

Highlights are a short collection of bullet points that convey the core findings of the article. Highlights are optional and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view example Highlights on our information site.

**Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

**Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

Highlights are mandatory for Original Reports and Reviews only. They are optional but encouraged for all other article types.

**Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

**Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Formatting of funding sources**

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
- EPS (or PDF): Vector drawings, embed all used fonts.
- TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
- TIFF (or JPEG): Bitmapted (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
- TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.
Color figures for exclusive use as cover illustration may be submitted by authors who are also submitting a manuscript for consideration. These figures should relate to the manuscript being submitted as well as the larger scope and focus of Epilepsy & Behavior.

Illustration services
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:
http://open.mendeley.com/use-citation-style/epilepsy-and-behavior
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

**Reference style**

**Text:** Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

**List:** Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

**Examples:**

Reference to a journal publication:


Reference to a journal publication with an article number:


Reference to a book:


Reference to a chapter in an edited book:


Reference to a website:


Reference to a dataset:


Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples of Formatted References).

**Journal abbreviations source**

Journal names should be abbreviated according to the List of Title Word Abbreviations.

**Video**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Mendeley Data**

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

**Data statement**

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

**AFTER ACCEPTANCE**

**Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Webshop. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com
Appendix D: Ethical approval letters
14 December 2017

Dr Emily Revell  
Clinical Psychology, School of Health in Social Science  
University of Edinburgh, Medical School (Doorway 6)  
Teviot Place, Edinburgh  
EH8 9AG

Dear Dr Revell

Study title: Developing a psychological understanding of idiopathic drop attacks
REC reference: 17/YH/0438
Protocol number: CAHSS1710/03
IRAS project ID: 233998

The Proportionate Review Sub-committee of the Yorkshire & The Humber - South Yorkshire Research Ethics Committee reviewed the above application on 14 December 2017.

We plan to publish your research summary wording for the above study on the HRA website, together with your contact details. Publication will be no earlier than three months from the date of this favourable opinion letter. The expectation is that this information will be published for all studies that receive an ethical opinion but should you wish to provide a substitute contact point, wish to make a request to defer, or require further information, please contact hra.studyregistration@nhs.net outlining the reasons for your request. Under very limited circumstances (e.g. for student research which has received an unfavourable opinion), it may be possible to grant an exemption to the publication of the study.
**Ethical opinion**

On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

**Conditions of the favourable opinion**

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

**Management permission must be obtained from each host organisation prior to the start of the study at the site concerned.**

*Management permission should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).*

*Guidance on applying for HRA Approval (England)/ NHS permission for research is available in the Integrated Research Application System, [www.hra.nhs.uk](http://www.hra.nhs.uk) or at [http://www.rdforum.nhs.uk](http://www.rdforum.nhs.uk).*

*Where a NHS organisation’s role in the study is limited to identifying and referring potential participants to research sites (“participant identification centre”), guidance should be sought from the R&D office on the information it requires to give permission for this activity.*

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

*Sponsors are not required to notify the Committee of management permissions from host organisations.*

**Registration of Clinical Trials**

All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database. This should be before the first participant is recruited but no later than 6 weeks after recruitment of the first participant.

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.

To ensure transparency in research, we strongly recommend that all research is registered but for non-clinical trials this is not currently mandatory.

If a sponsor wishes to request a deferral for study registration within the required timeframe, they should contact [hra.studyregistration@nhs.net](mailto:hra.studyregistration@nhs.net). The expectation is that all clinical trials will be registered, however, in exceptional circumstances non registration may be permissible with prior agreement from the HRA. Guidance on where to register is provided on the HRA website.
It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

**Ethical review of research sites**

The favourable opinion applies to all NHS sites taking part in the study, subject to management permission being obtained from the NHS/HSC R&D office prior to the start of the study (see “Conditions of the favourable opinion”).

**Summary of discussion at the meeting**

**Social or scientific value; scientific design and conduct of the study**

Members requested further information on the process for participants to be involved in analysing the results as mentioned in the Participant Information Sheet and A62 of the IRAS form. This "option" was not detailed in A18 of the IRAS form and was not mentioned in the protocol, members requested that these were to be amended.

You replied that participants would be invited to review the themes that were identified within their interviews. This would take the form of the researcher presenting the themes and recording whether participants agreed with them or not. This would help the researcher to ensure that their analysis was valid. The text had been added to both A18 of the IRAS form and the protocol accordingly.

Members requested justification on why no PPI was completed for this study as stated in A14-1 of the IRAS form.

You replied as the experiences that this research was hoping to explore were very specific to a relatively small group of people, it was not appropriate to consult members of the public. As those who have experienced drop attacks were potential participants, consultation with these people may have introduced bias and made them unsuitable as participants. Therefore, in order to maintain as large a participant pool as possible, only consultation with experienced professionals in the field was undertaken in order to shape the study. The text has been added to A14-1.

The Sub Committee was satisfied with the responses given to the issues raised.

**Recruitment arrangements and access to health information, and fair participant selection**

Members requested clarification on whether all potential participants should "Opt in" as was the planned recruitment via letter. The Participant Covering Letter should be given by the introducing Neurologist along with the Participant Information Sheet in the OPD clinic so the potential participant could take all the information away to consider and then decide.

You replied that the covering letter would be given to all participants along with the Participant Information Sheet when meeting with the neurologist in the outpatient clinic.

The Sub Committee was satisfied with the response given to the issue raised.

**Care and protection of research participants; respect for potential and enrolled participants’ welfare and dignity**
Members requested confirmation of the process to ensure ALL audio recording were permanently deleted and not recoverable from the audio recording device and for which this process should meet NHS data protection requirements as stated at A37 of the IRAS form.

You replied that all audio recordings would be permanently erased from the audio recording devices, using software designed for this purpose and NHS Lothian policy on audio recordings would be followed at all times. This had been added at A37 of the IRAS form.

Members stated that having made the case that research in this area was lacking and potentially of great significance, the research needed to be registered by placing information in the public domain that it was being undertaken from the beginning. An acceptable means of registering the research was by placing the accepted Research Summary (A6.1) with appropriate contact details for the research team on an appropriate publicly accessible website i.e. Trust, University, Charity website which was searchable by any of the common internet search engines. Therefore A50 of the IRAS form needed to be amended.

You replied that the research study would be uploaded to clinicaltrials.gov and would therefore be publicly accessible and amended A50 accordingly.

The Sub Committee was satisfied with the responses given to the issues raised.

Approved documents

The documents reviewed and approved were:

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Employers liability]</td>
<td></td>
<td>01 August 2017</td>
</tr>
<tr>
<td>GP/consultant information sheets or letters [GP Letter V1]</td>
<td>1</td>
<td>13 November 2017</td>
</tr>
<tr>
<td>Interview schedules or topic guides for participants [Interview guide (for interviewer) V1]</td>
<td>1</td>
<td>13 November 2017</td>
</tr>
<tr>
<td>Interview schedules or topic guides for participants [Audio Diary Guide V1]</td>
<td>1</td>
<td>13 November 2017</td>
</tr>
<tr>
<td>IRAS Application Form [IRAS_Form_13122017]</td>
<td></td>
<td>13 December 2017</td>
</tr>
<tr>
<td>Letters of invitation to participant [Participant covering letter]</td>
<td>1</td>
<td>13 November 2017</td>
</tr>
<tr>
<td>Other [Clinical Trial Liability Confirmation]</td>
<td></td>
<td>27 July 2017</td>
</tr>
<tr>
<td>Other [Public Liability Confirmation]</td>
<td></td>
<td>26 July 2017</td>
</tr>
<tr>
<td>Other [Professional Indemnity Insurance]</td>
<td></td>
<td>04 August 2017</td>
</tr>
<tr>
<td>Participant consent form [Consent Form V1]</td>
<td>1</td>
<td>13 November 2017</td>
</tr>
<tr>
<td>Participant information sheet (PIS) [Participant Information Sheet V1]</td>
<td>1</td>
<td>13 November 2017</td>
</tr>
<tr>
<td>Referee’s report or other scientific critique report [Supervisors’ project appraisal]</td>
<td>1</td>
<td>03 August 2017</td>
</tr>
<tr>
<td>Research protocol or project proposal</td>
<td>Version 2</td>
<td>12 December 2017</td>
</tr>
<tr>
<td>Summary CV for Chief Investigator (CI) [Emily Revell CV]</td>
<td></td>
<td>13 November 2017</td>
</tr>
<tr>
<td>Summary CV for supervisor (student research) [Paul Morris CV]</td>
<td></td>
<td>23 November 2017</td>
</tr>
</tbody>
</table>

Membership of the Proportionate Review Sub-Committee

A Research Ethics Committee established by the Health Research Authority
The members of the Sub-Committee who took part in the review are listed on the attached sheet.

**Statement of compliance**

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

**After ethical review**

**Reporting requirements**

The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.

**User Feedback**

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: [http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/](http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/)

**HRA Training**

We are pleased to welcome researchers and R&D staff at our training days – see details at [http://www.hra.nhs.uk/hra-training/](http://www.hra.nhs.uk/hra-training/)

With the Committee's best wishes for the success of this project.

---

17/YH/0438 Please quote this number on all correspondence

Yours sincerely

A Research Ethics Committee established by the Health Research Authority
Dr Ian Woollands  
Chair  

Email: nrescommittee.yorkandhumber-southyorks@nhs.net

Enclosures:  
List of names and professions of members who took part in the review  
“After ethical review – guidance for researchers”

Copy to:  
Ms Charlotte Smith, University of Edinburgh  
Miss Melissa Taylor, NHS Lothian
Yorkshire & The Humber - South Yorkshire Research Ethics Committee

Attendance at PRS Sub-Committee of the REC meeting on 14 December 2017 via correspondence.

Committee Members:

<table>
<thead>
<tr>
<th>Name</th>
<th>Profession</th>
<th>Present</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Ahmed H Abdelhafiz</td>
<td>Consultant Physician, Elderly Medicine</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Mr Martin Edmunds</td>
<td>Editor</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Dr Ian Woollands (Chair)</td>
<td>Retired Clinical Director, Occupational Health</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

Also in attendance:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position (or reason for attending)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miss Kerry Dunbar</td>
<td>REC Manager</td>
</tr>
</tbody>
</table>
Dear Dr Gillespie

Lothian R&D Project No: 2017/0335
Title of Research: Developing a psychological understanding of idiopathic drop attacks

Participant Information Sheet: Version 1 dated 13 November 2017
Protocol: Version 2.0 dated 12 December 2017

REC No: 17/YH/0438
Consent Form (Main Cohort): Version 1 dated 13 November 2017

I am pleased to inform you this letter provides Site Specific approval for NHS Lothian for the above study and you may proceed with your research, subject to the conditions below.

Please note that the NHS Lothian R&D Office must be informed of any changes to the study such as amendments to the protocol, funding, recruitment, personnel or resource input required of NHS Lothian.

Substantial amendments to the protocol will require approval from the ethics committee which approved your study and the MHRA where applicable.

Please keep this office informed of the following study information, which is a condition of NHS Lothian R&D Management Approval:

1. Date you are ready to begin recruitment, date of the recruitment of the first participant and the monthly recruitment figures thereafter.
2. Date the final participant is recruited and the final recruitment figures.
3. Date your study / trial is completed within NHS Lothian.

I wish you every success with your study.

Yours sincerely

Dr Douglas Young
Principal R&D Manager

CC: Mr Michael Pearson, General Manager, Surgical Services Directorate, RIE
    Dr Emily Revell, Chief Investigator, NHS Lothian
Appendix E: Study protocol

Developing a psychological understanding of idiopathic drop attacks

Study Protocol

Version 3

Emily Revell
15th January 2018
1 Introduction

Idiopathic drop attacks (IDAs) have been defined as falls to the floor without warning, where there is no identified organic cause, despite diagnostic testing. They are not caused by malfunction of the lower limbs, changes in body or head posture, or vertigo. There is also no loss of consciousness and recovery is rapid. Despite this fast recovery, people can experience significant injuries and fear about further falls, impacting on their everyday functioning.

This phenomenon was highlighted by Stevens and Matthews (1973) who recruited 33 patients from a neurology clinic and seven from a gynaecological clinic. They also approached 100 men who were admitted for routine surgery but found that none of these had experienced drop attacks. Therefore their sample was entirely female, with onset occurring on average at age 44. Although the age-range of onset spanned from 19 to 69, in two thirds of the sample onset was between the ages of 40 and 59.

The authors ruled out obesity, vascular disease, epilepsy, vestibular disease, limb weakness and hypothyroidism as contributing to IDAs. They investigated hormonal changes, given that the age of onset coincided with when menopause could be likely to start and due to the fact that 60% of the younger patients had onset of IDAs during pregnancy. Despite this, the authors found no clear links between hormonal changes and IDAs, although 45% did experience onset either during pregnancy or within 3 years either side of the start of the menopause.

The frequency of IDAs varied greatly between individuals but ranged from two to more than 12 falls per year, usually while walking. This was more likely to happen when out of the house but over half of the sample also reported falling at home. These falls would lead to injury to the knees and often also to the hands, chest and face. 18% reported having fractured or broken bones as a result of an IDA. Given the age of onset, the increased likelihood of osteoporosis would also increase the risk of more severe injury as a result of IDAs. The authors also reported that many women would become afraid to go out due to both the risk of injury and embarrassment.

Although it is undocumented, the prevalence of IDAs could be relatively high. As part of their recruitment process, the Stevens and Matthews (1973) asked 200 consecutive patients at a gynaecology clinic whether they had experienced falls and
found that 3.5% met the criteria for IDA. This suggests that this phenomenon could account for a significant number of falls in women in the general population.

There are similarities between IDAs and psychogenic non-epileptic seizures (PNES). However, IDAs are not included widely included in studies of PNES, which tend to focus on ‘convulsive’ seizures. Hubsch et al. (2011) analysed clinical signs in 145 PNES and identified different subtypes of seizure, none of which covered IDAs. However, Galimberti et al (2003) and Devinsky et al (1996) included patients with IDA within a PNES sample, accounting for around 10% of each sample. There has been no published research investigating this group in isolation since Stevens and Matthew’s (1973) study other than a small number of case reports (Butsch & Schneemann, 2014), one of which identified a woman’s IDAs as occurring following recollection of traumatic experiences, suggesting a psychological mechanism (Wilner et al., 2010).

A paper which is currently being prepared for submission by Dr Hoeritzauer, Dr Carson & Dr Stone at the Department of Clinical Neurosciences, Edinburgh, identified 83 patients who had attended a neurology clinic over nine years who described experiencing these attacks. This led the authors to develop a hypothesis that IDAs are a conditioned behavioural response to negative external (environmental or situational) or internal (anxiety symptoms or dissociation) stimuli. This association is maintained through fear of collapse and/or through the fall providing relief from the negative stimuli. This type of mechanism has been highlighted previously in functional neurological disorders, where limbic regions were found to have a greater influence on motor preparatory regions when in a state of arousal (Voon et al., 2011).

As the underlying mechanism of IDAs is unknown, there is currently no treatment available. However, Hoeritzauer and colleagues report that a small number of patients saw their IDAs resolve following an explanation of the episodes as conditioned responses and the use of distraction techniques. A psychological understanding of the problem could help to identify a potential psychological intervention. Such interventions have been found to be effective for PNES, particularly cognitive behavioural therapy (Goldstein et al., 2010). This type of intervention could focus on helping individuals to manage their condition and improve the ways they cope with the anxiety surrounding future falls, rather than necessarily seek to resolve the IDAs.
This research aims to explore a psychological understanding of drop attacks. This will be investigated through the collection of qualitative data from interviews and recorded diaries from individuals experiencing IDAs. The data will be analysed using a grounded theory approach in order to better understand the onset of drop attacks, the impact of life stressors as well as thoughts, feelings and behaviour both directly before and after a IDA.

2 Aims
The main aim of this research is to develop a psychological understanding of idiopathic drop attacks. The primary research question is as follows:

- What are the predisposing and precipitating factors related to the onset of IDAs?

Secondary research questions are:

- What are individuals' thoughts, emotions and behaviour immediately prior to an IDA?
- What are individuals' thoughts, emotions and behaviour immediately following an IDA?

3 Methods

3.1 Participants
Participants will be ten individuals who are experiencing ongoing IDAs. Inclusion criteria are 1) Aged 18+, 2) IDAs occurring 6+ times per year, 3) Able to provide informed consent. Exclusion criteria are 1) Diagnosis which would provide an alternative explanation for drop attacks.

3.2 Design
In this exploratory qualitative study, neurology outpatients with ongoing IDAs will undergo psychological assessment and complete written diaries for eight weeks. Throughout the study, participants will receive treatment as usual from a neurologist.

3.3 Procedure
Participants will be recruited from a neurology outpatient clinic at the Department of Clinical Neurosciences in Edinburgh where they will be approached by their
consultant who will give them a participant information sheet. If they are interested in taking part, a meeting will be set up with the researcher to discuss the study further and obtain written informed consent.

Participants will then meet with the researcher to complete an initial psychological interview which will be audio recorded. This interview will follow a standard initial psychological interview structure and will aim to gain information about the person’s experiences of IDAs, along with relevant personal and social history. The interview schedule is included in appendix 1.

Following this initial interview, participants will be asked to record written accounts of any IDA, detailing their thoughts, physical arousal, feelings and behaviour, as close to the event as possible. They will be encouraged to record detailed accounts, outlining the period before, during and after the episode, in order to identify any potential triggers. They will be shown an example of a completed diary in order to help them to understand what they need to do. Participants will be asked to record such events over a period of eight weeks during which the researcher will contact them fortnightly to discuss any difficulties or concerns. If participants do not experience any drop attacks during this period, they will be asked if they want to continue recording diaries for an additional two to four weeks.

Following completion of this period, participants will meet again with the researcher to return the diaries and discuss any patterns noticed in the interview and diaries. The researcher will also answer any further questions that the participant has about the study.

3.4 Measures

3.4.1 Semi-structured assessment interview
This audio-recorded 60-minute interview will follow the format of an initial psychological assessment and will allow discussion of presenting problems and relevant personal and social history. This will allow potential predisposing and precipitating factors to be identified. Participants’ experiences of IDAs will also be discussed, focussing on thoughts, feelings and behaviour before and after the episodes. The participants will also be asked about the impact that these have had on their everyday functioning.
3.4.2 IDA record
Participants will be asked to write an account of any IDAs. They will be shown an example diary and will also be given a prompt sheet, asking them to recall any triggers, feelings, physical arousal, thoughts and behaviour both directly before and after the episode. This diary will be completed by participants as close to the episode as possible.

4 Sample size
In order to address all three of the research questions, a qualitative approach will be used. An overall sample size of ten should be sufficient to allow themes to be identified. A purposive sampling method will be used to recruit younger participants as well as those who are in the average age range for onset. This will allow any differences between these two groups to be explored further. As the inclusion criteria specifies 6+ IDAs per year, this will ensure a fairly homogenous sample in terms of frequency of IDAs.

There is a sample of approximately 40 patients who had ongoing drop attacks in July 2016 which can be recruited from. One to two new referrals per month are currently being made to Dr Jon Stone, and these patients can also be approached. This is a relatively small pool and there can be some unwillingness to engage with a psychological approach within the functional neurological population. However, as this study is aiming to help better understand participants’ experiences, rather than investigating psychological treatment, this may enhance engagement. Attrition is also a factor but, as the primary research question relies on information from the initial interview, the risk of this is reduced. Therefore, recruiting a purposive sample of ten participants should be achievable.

5 Analysis
The content of the psychological interviews and diaries will be analysed using a grounded theory approach in order to meet all of the study objectives. Using both initial interviews and recorded accounts will allow information to be obtained from different viewpoints, enriching the data. This data will be coded by initially naming each segment of data and then synthesising the most common codes to identify themes. From these, theories can be developed regarding predisposing and precipitating factors. Themes regarding thoughts, emotions and behaviour can also be explored.
Participants will be invited to review the themes that were identified within their interviews. This will take the form of the researcher presenting the themes and recording whether participants agree with them or not. This will help the researcher to ensure that the analysis is valid.

6 Timetable
- Recruitment start – January 2018
- Data collection start – January 2018
- Data collection finish – December 2018
- Analysis – January 2019
- Article ready for submission – April 2019

7 References


Galimberti, C., Ratti, M., Murelli, R. et al. (2003). Patients with psychogenic nonepileptic seizures, alone or epilepsy-associated, share a psychological profile distinct from that of epilepsy patients. *J Neurol, 250*(3), 338-346. DOI:10.1007/s00415-003-1009-0


INTRODUCTION

Thank you for agreeing to be interviewed as part of this research project. As you are aware, this interview is being recorded.

Anything you tell me will be kept confidential. The only time I may need to break this confidentiality is if I believe there is a risk of harm to either yourself or others. If this comes up, we can discuss it and make a plan together.

I am going to ask you some questions about your drop attacks and other aspects of your life to try to help me understand what it is like for you. If at any point you feel that you do not want to continue, or if you don’t want to answer any questions, please let me know.

Do you have any questions?
**Drop attacks**

- Description of attacks
  - Can you tell me a bit about your drop attacks?

- Why was help sought?
  - Why and when did you start seeing Dr Stone?

- Recent examples of drop attacks (with as much detail as possible)
  - Can you tell me about the last drop attack you had?

- Frequency, duration, severity, distress
  - How often do you have them?
  - How long do they last?
  - What do they feel like? (0-100 rating for intensity of emotion)
  - How do you feel before/after? (0-100 rating for intensity of emotion)
  - Do you have injuries as a result?

- How the problem impacts on functioning/interferes with daily life
  - Do the drop attacks make it hard to do other things?
  - If you didn’t have drop attacks, what would your life look like?
  - On a scale of 1-100, how much does it interfere with your life?

- Situational triggers
  - Do the attacks happen in particular places/times/with certain people?

- Modulators
  - Is there anything that makes them not as bad/frequent?
  - Is there anything that makes them worse?

- Avoidance
  - Is there anything that you don’t do anymore because of the drop attacks?
  - Have they changed the way you do things?

- Coping strategies – adaptive or maladaptive
  - What helps you to cope?
  - On a scale of 1-100, how well do you feel you are coping with them?

- Beliefs about the problem
  - Why do you think the drop attacks happen?
  - What do your close family members/friends think about the drop attacks?
  - What is Dr Stone’s explanation? Does this sound right to you?
  - How much control do you think you have over the drop attacks? (0-100 rating)
  - How much control do you think Dr Stone / your medical team has over the drop attacks? (0-100 rating)

**History and Onset of Problems**

- When did you first start having drop attacks?
- Can you tell me about the first time it happened?
• Precipitants
  • What was going on when they first started?
  • Had there been any changes in your life?
  • Was anything stressful happening in your life at the time?
  • Why do you think they started? Why then?

• Time course
  • Have the drop attacks changed over time?
  • Have they got better/worse?

• Previous episodes
  • Have you had drop attacks or something similar another time in your life?
  • Was there anything that helped then?
  • Did you see anyone about them then?

• Family history
  • Is there a family history of drop attacks/related disorders/medical issues/mental health issues?

**Mood/mental state**

• General enquiries about distress, concerns and well-being– stability/changes

• Co-morbidity
  • How do you generally feel in yourself?
  • Do you ever feel down/low mood?
  • Do you ever feel anxious/worried/stressed?
  • Has this changed recently or has it been stable?
  • Have you felt down or anxious at some point in the past?

• Other difficulties
  • How is your sleep?
  • How is your appetite?
  • Do you find it hard to concentrate?

• Self-harm/suicidality – risk assessment

• Current functioning
  • What does your day look like at the moment?
  • Has this changed recently?

**Optional/Additional questions**

**Developmental/Personal History**

• Early memories – including experience of trauma/abuse/neglect/losses
  • What was it like for you growing up?

• Relationships with parents, siblings, significant others
  • Who was around when you were growing up?
  • How did you get on with....?
• Primary and Secondary School
  • Can you tell me a bit about school?
  • How did you find the academic work?
  • Did you have friends?

• Educational/occupational history - timeline
  • When did you leave school?
  • What did you do afterwards?

• Experiences of social exclusion, discrimination, stigma etc
  • Have you ever not been able to do something you wanted to do?
  • Do you feel you’ve been discriminated against?

• Medical history
  • Have you ever had any major illnesses or health problems?
  • Have you ever spent any time in hospital?

• Is there anything else I should know about?

Psychosocial Factors

• Interpersonal relationships
  • Who is in your life at the moment?
  • Do you have a partner/children?
  • Tell me about your friends
  • Who do you talk to if you have a problem/need support?

• Occupation
  • Do you work? What do you do?
  • Do you enjoy it?
  • What did you do in the past?

• Accommodation/financial worries
  • Do you worry about money?
  • Are you happy with where you live and who you live with?

• Hobbies/interests
  • What hobbies/interests do you have?
  • Is there anything you used to do that you don’t do anymore?
  • Is there anything you’d like to do?

• Alcohol/Cigarettes/Drugs

• Other concerns
  • Is there anything else in your life at the moment that worries you or that you’d like to be different?

Thank you very much for talking to me today. Is there anything else that we haven’t talked about that you feel is relevant? Do you have any questions you’d like to ask me?
Appendix G: Diary prompt sheet

DIARY GUIDE
Investigating drop attacks

Please use these guidelines when making your written diaries. However, there is no right or wrong information to record and this is a guide only.

Try to record your diary as soon after the drop attack as you can. Try to write after every drop attack you have.

Try to give as detailed an account of what happened before the attack, during the attack and afterwards. You can use the following questions to help you to remember different aspects of the experience:

**Before**
- What had you been doing in the hours before the drop attack?
- What had you been doing immediately beforehand?
- Who were you with? Where were you? What was the environment like?
- How were you feeling beforehand? Happy, sad, stressed, worried, excited etc.
- How did your body feel? Any aches/pains? Shaking or unsteadiness?
- What was going through your head? What was on your mind?

**During**
- Try to describe the drop attack.
- What do you remember about it?
- How did your body feel?
- How did it feel? Were you frightened/embarrassed/calm?
- Was there anything going through your head?
- Were other people around? How did they react?

**After**
- What happened afterwards?
- Did other people help you? What was that like?
- How did you feel (e.g. happy, sad, calm, upset, scared, relieved, worried etc.)
- What were you thinking about what had just happened?
- What did you do next? Did you change your plans?
- Did you need to take time to recover?

If you have any questions about writing your diary, please contact me on Tel: xxxxxxxxxxxx
Appendix H: Excerpt of transcript and initial codes
P02 interview transcript

Do you want to start by telling me a little bit about your drop attacks?

Em, they first started, no I’m (age) this month so they must have started about 30 years ago. It was shortly after I was diagnosed with Meniere’s disease which was very bad then. I was always taking really bad vertigo attacks, sickness and diarrhoea, all that. Back then the drop attacks weren’t regular at all, I would maybe have one or two a year. Hardly any more and I could go longer than that without any. So I just assumed it was part of Meniere’s disease. So it’s really in the last, I would say, I’ve noticed in the last roughly 10 years, when the vertigo attacks have really not been such a bother to me, the drop attacks became far more common. Again I was just putting it down to being related to Meniere’s disease, but when I started seeing Dr Stone, it must have been the end of last year, it’s hard to remember. He reckoned that, because my Meniere’s was easing, the drop attacks had somehow taken over from that. So with the drop attacks, they can happen anytime. I suffer from dizziness and giddiness, light-headedness quite a lot. Certainly when I was working, up until I retired in March, the drop attacks were much worse. But they didn’t necessarily happen after, or when I was feeling giddy or dizzy. I could be feeling absolutely normal and literally just fall. I’ve been trying to work out is it anything I’ve eaten, anything I’ve drunk. I can’t see any pattern there at all.

One pattern I have noticed is because I suffer with anxiety with my Meniere’s disease, and I’m on paroxetine for that, if I get very anxious or stressed, that’s very much when they can come more frequency. I’ve actually brought some notes with me for you. I started taking notes months ago but since March they’ve gone down a lot and I’ve been very absent minded about taking the notes recently. Very often if I’m travelling, I’ll have a drop attack. I very often go on holiday on my own, because I’m determined not to let the condition really control my lifestyle. And I love going on holiday. And there’s always somebody around when you collapse in a heap. But I noticed… There was one time, I think about a couple of years ago, my plane to (destination 1) was delayed by three days for bad ongoing weather and I had a collapse in the airport then. I could feel myself getting a little bit anxious and uptight. Because with my deafness as well I wasn’t quite sure what was going on. And as I was going to collect my case back from the airport, I had a collapse in the general luggage place. Another time a few years previously, I boarded a plane to (destination 2) and I hadn’t booked any seat so everybody was dashing on and it was hot and everybody, tempers were getting frayed and whatever. And with the heat and with all that was going on around me, again I had a drop attack then.

Last year, when I was in (destination 3) with an ex of mine I had a drop attack on the morning of the day I was going to get a plane home in the evening and I was just walking along a path near the beach on my own. He was a very Jekyll and Hyde character and for 7 days out of the 14 he was shouting at me on the holiday for no reason at all and that morning he had started that so I just left the apartment to go away on my own but I was still stressed. All of a sudden I just collapsed. I don’t normally black out for long. It’s hard to tell if I’m actually totally blacking out. But what I do find when I’m on the ground is that I’m very often aware of people being around me but I can’t respond. I can’t answer then. Very often I get a lot of spit and I’ve got to spit quite a bit while I’m still on the ground. I’m lucky in that... Well that particular time last year I was taken by ambulance to the hospital in (destination 3) and they wanted to keep me in but I knew myself there was no need to keep me in. Because even by the time I arrived at the hospital I was absolutely ok.
Prostate Glands Worsen When Working (stress)

- Elevated IgG levels
- Elevated IgG levels
- Elevated IgG levels

Feeds trigger to stressful situations

Stress makes tails more frequent

- Seeing while traveling
- Seeing while traveling
- Seeing while traveling

Important to have people around if you fail

Stress and anxiety contributing factors

- Cheese after stressful life events
- Falling outside
- Falling while standing or walking
- Falling while standing (disordered)
- Stress reduced recently
Appendix I: Funnel plots

Funnel plot of studies in the between-groups daily functioning comparison

Funnel plot of studies in the repeated measures daily functioning comparison
Funnel plot of studies in the between-groups functional symptoms comparison

Funnel plot of studies in the repeated measures functional symptoms comparison
Funnel plot of studies in the between-groups depression symptoms comparison

Funnel plot of studies in the between-groups anxiety symptoms comparison
Funnel plot of studies in the repeated measures depression symptoms comparison

Funnel plot of studies in the repeated measures anxiety symptoms comparison